ch.fhir.ig.ch-crl 0.9.0

package/CodeSystem-nkrs-alphafetoprotein.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-alphafetoprotein","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-alphafetoprotein defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">0<a name=\"nkrs-alphafetoprotein-0\"> </a></td><td>AFP0</td><td>Within reference range</td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-alphafetoprotein-1\"> </a></td><td>AFP1</td><td>&gt; upper limit of reference range to &lt; 1’000 ng/ml</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-alphafetoprotein-2\"> </a></td><td>AFP2</td><td>1’000 – 10’000 ng/ml</td></tr><tr><td style=\"white-space:nowrap\">3<a name=\"nkrs-alphafetoprotein-3\"> </a></td><td>AFP3</td><td>&gt; 10’000 ng/ml</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-alphafetoprotein","version":"0.9.0","name":"NkrsAlphaFetoprotein","title":"NKRS - α-fetoprotein","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The data item records the serum level of the tumour marker α-fetoprotein (AFP).   \r\n\r\n**α-fetoprotein (Variable number: 5.5.1)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-alphafetoprotein","content":"complete","count":4,"concept":[{"code":"0","display":"AFP0","definition":"Within reference range"},{"code":"1","display":"AFP1","definition":"> upper limit of reference range to < 1’000 ng/ml"},{"code":"2","display":"AFP2","definition":"1’000 – 10’000 ng/ml"},{"code":"3","display":"AFP3","definition":"> 10’000 ng/ml"}]}

package/CodeSystem-nkrs-annarborstaging.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-annarborstaging","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-annarborstaging defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">I<a name=\"nkrs-annarborstaging-I\"> </a></td><td>Stage I</td></tr><tr><td style=\"white-space:nowrap\">I+A<a name=\"nkrs-annarborstaging-I.43A\"> </a></td><td>Stage I+A</td></tr><tr><td style=\"white-space:nowrap\">I+B<a name=\"nkrs-annarborstaging-I.43B\"> </a></td><td>Stage I+B</td></tr><tr><td style=\"white-space:nowrap\">IE<a name=\"nkrs-annarborstaging-IE\"> </a></td><td>Stage IE</td></tr><tr><td style=\"white-space:nowrap\">IE+A<a name=\"nkrs-annarborstaging-IE.43A\"> </a></td><td>Stage IE+A</td></tr><tr><td style=\"white-space:nowrap\">IE+B<a name=\"nkrs-annarborstaging-IE.43B\"> </a></td><td>Stage IE+B</td></tr><tr><td style=\"white-space:nowrap\">I(E)<a name=\"nkrs-annarborstaging-I.40E.41\"> </a></td><td>Stage I(E)</td></tr><tr><td style=\"white-space:nowrap\">I(E)+A<a name=\"nkrs-annarborstaging-I.40E.41.43A\"> </a></td><td>Stage I(E)+A</td></tr><tr><td style=\"white-space:nowrap\">I(E)+B<a name=\"nkrs-annarborstaging-I.40E.41.43B\"> </a></td><td>Stage I(E)+B</td></tr><tr><td style=\"white-space:nowrap\">II<a name=\"nkrs-annarborstaging-II\"> </a></td><td>Stage II</td></tr><tr><td style=\"white-space:nowrap\">II+A<a name=\"nkrs-annarborstaging-II.43A\"> </a></td><td>Stage II+A</td></tr><tr><td style=\"white-space:nowrap\">II+B<a name=\"nkrs-annarborstaging-II.43B\"> </a></td><td>Stage II+B</td></tr><tr><td style=\"white-space:nowrap\">IIE<a name=\"nkrs-annarborstaging-IIE\"> </a></td><td>Stage IIE</td></tr><tr><td style=\"white-space:nowrap\">IIE+A<a name=\"nkrs-annarborstaging-IIE.43A\"> </a></td><td>Stage IIE+A</td></tr><tr><td style=\"white-space:nowrap\">IIE+B<a name=\"nkrs-annarborstaging-IIE.43B\"> </a></td><td>Stage IIE+B</td></tr><tr><td style=\"white-space:nowrap\">II(E)<a name=\"nkrs-annarborstaging-II.40E.41\"> </a></td><td>Stage II(E)</td></tr><tr><td style=\"white-space:nowrap\">II(E)+A<a name=\"nkrs-annarborstaging-II.40E.41.43A\"> </a></td><td>Stage II(E)+A</td></tr><tr><td style=\"white-space:nowrap\">II(E)+B<a name=\"nkrs-annarborstaging-II.40E.41.43B\"> </a></td><td>Stage II(E)+B</td></tr><tr><td style=\"white-space:nowrap\">III<a name=\"nkrs-annarborstaging-III\"> </a></td><td>Stage III</td></tr><tr><td style=\"white-space:nowrap\">III+A<a name=\"nkrs-annarborstaging-III.43A\"> </a></td><td>Stage III+A</td></tr><tr><td style=\"white-space:nowrap\">III+B<a name=\"nkrs-annarborstaging-III.43B\"> </a></td><td>Stage III+B</td></tr><tr><td style=\"white-space:nowrap\">IIIE<a name=\"nkrs-annarborstaging-IIIE\"> </a></td><td>Stage IIIE</td></tr><tr><td style=\"white-space:nowrap\">IIIE+A<a name=\"nkrs-annarborstaging-IIIE.43A\"> </a></td><td>Stage IIIE+A</td></tr><tr><td style=\"white-space:nowrap\">IIIE+B<a name=\"nkrs-annarborstaging-IIIE.43B\"> </a></td><td>Stage IIIE+B</td></tr><tr><td style=\"white-space:nowrap\">III(E)<a name=\"nkrs-annarborstaging-III.40E.41\"> </a></td><td>Stage III(E)</td></tr><tr><td style=\"white-space:nowrap\">III(E)+A<a name=\"nkrs-annarborstaging-III.40E.41.43A\"> </a></td><td>Stage III(E)+A</td></tr><tr><td style=\"white-space:nowrap\">III(E)+B<a name=\"nkrs-annarborstaging-III.40E.41.43B\"> </a></td><td>Stage III(E)+B</td></tr><tr><td style=\"white-space:nowrap\">IIIS<a name=\"nkrs-annarborstaging-IIIS\"> </a></td><td>Stage IIIS</td></tr><tr><td style=\"white-space:nowrap\">IIIS+A<a name=\"nkrs-annarborstaging-IIIS.43A\"> </a></td><td>Stage IIIS+A</td></tr><tr><td style=\"white-space:nowrap\">IIIS+B<a name=\"nkrs-annarborstaging-IIIS.43B\"> </a></td><td>Stage IIIS+B</td></tr><tr><td style=\"white-space:nowrap\">III(S)<a name=\"nkrs-annarborstaging-III.40S.41\"> </a></td><td>Stage III(S)</td></tr><tr><td style=\"white-space:nowrap\">III(S)+A<a name=\"nkrs-annarborstaging-III.40S.41.43A\"> </a></td><td>Stage III(S)+A</td></tr><tr><td style=\"white-space:nowrap\">III(S)+B<a name=\"nkrs-annarborstaging-III.40S.41.43B\"> </a></td><td>Stage III(S)+B</td></tr><tr><td style=\"white-space:nowrap\">IIIES<a name=\"nkrs-annarborstaging-IIIES\"> </a></td><td>Stage IIIES</td></tr><tr><td style=\"white-space:nowrap\">IIIES+A<a name=\"nkrs-annarborstaging-IIIES.43A\"> </a></td><td>Stage IIIES+A</td></tr><tr><td style=\"white-space:nowrap\">IIIES+B<a name=\"nkrs-annarborstaging-IIIES.43B\"> </a></td><td>Stage IIIES+B</td></tr><tr><td style=\"white-space:nowrap\">III(E)S<a name=\"nkrs-annarborstaging-III.40E.41S\"> </a></td><td>Stage III(E)S</td></tr><tr><td style=\"white-space:nowrap\">III(E)S+A<a name=\"nkrs-annarborstaging-III.40E.41S.43A\"> </a></td><td>Stage III(E)S+A</td></tr><tr><td style=\"white-space:nowrap\">III(E)S+B<a name=\"nkrs-annarborstaging-III.40E.41S.43B\"> </a></td><td>Stage III(E)S+B</td></tr><tr><td style=\"white-space:nowrap\">IIIE(S)<a name=\"nkrs-annarborstaging-IIIE.40S.41\"> </a></td><td>Stage IIIE(S)</td></tr><tr><td style=\"white-space:nowrap\">IIIE(S)+A<a name=\"nkrs-annarborstaging-IIIE.40S.41.43A\"> </a></td><td>Stage IIIE(S)+A</td></tr><tr><td style=\"white-space:nowrap\">IIIE(S)+B<a name=\"nkrs-annarborstaging-IIIE.40S.41.43B\"> </a></td><td>Stage IIIE(S)+B</td></tr><tr><td style=\"white-space:nowrap\">III(E)(S)<a name=\"nkrs-annarborstaging-III.40E.41.40S.41\"> </a></td><td>Stage III(E)(S)</td></tr><tr><td style=\"white-space:nowrap\">III(E)(S)+A<a name=\"nkrs-annarborstaging-III.40E.41.40S.41.43A\"> </a></td><td>Stage III(E)(S)+A</td></tr><tr><td style=\"white-space:nowrap\">III(E)(S)+B<a name=\"nkrs-annarborstaging-III.40E.41.40S.41.43B\"> </a></td><td>Stage III(E)(S)+B</td></tr><tr><td style=\"white-space:nowrap\">IV<a name=\"nkrs-annarborstaging-IV\"> </a></td><td>Stage IV</td></tr><tr><td style=\"white-space:nowrap\">IV+A<a name=\"nkrs-annarborstaging-IV.43A\"> </a></td><td>Stage IV+A</td></tr><tr><td style=\"white-space:nowrap\">IV+B<a name=\"nkrs-annarborstaging-IV.43B\"> </a></td><td>Stage IV+B</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-annarborstaging","version":"0.9.0","name":"NkrsAnnArborStaging","title":"NKRS - Ann Arbor Staging","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"This data item is a last modification of the Ann Arbor classification for lymphoma. \r\n\r\n**Ann Arbor staging (Variable number: 4.18)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.2, Part A, BASIC VARIABLES for Adults, Adolescents, and Children\\'","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-annarborstaging","content":"complete","count":48,"concept":[{"code":"I","display":"Stage I"},{"code":"I+A","display":"Stage I+A"},{"code":"I+B","display":"Stage I+B"},{"code":"IE","display":"Stage IE"},{"code":"IE+A","display":"Stage IE+A"},{"code":"IE+B","display":"Stage IE+B"},{"code":"I(E)","display":"Stage I(E)"},{"code":"I(E)+A","display":"Stage I(E)+A"},{"code":"I(E)+B","display":"Stage I(E)+B"},{"code":"II","display":"Stage II"},{"code":"II+A","display":"Stage II+A"},{"code":"II+B","display":"Stage II+B"},{"code":"IIE","display":"Stage IIE"},{"code":"IIE+A","display":"Stage IIE+A"},{"code":"IIE+B","display":"Stage IIE+B"},{"code":"II(E)","display":"Stage II(E)"},{"code":"II(E)+A","display":"Stage II(E)+A"},{"code":"II(E)+B","display":"Stage II(E)+B"},{"code":"III","display":"Stage III"},{"code":"III+A","display":"Stage III+A"},{"code":"III+B","display":"Stage III+B"},{"code":"IIIE","display":"Stage IIIE"},{"code":"IIIE+A","display":"Stage IIIE+A"},{"code":"IIIE+B","display":"Stage IIIE+B"},{"code":"III(E)","display":"Stage III(E)"},{"code":"III(E)+A","display":"Stage III(E)+A"},{"code":"III(E)+B","display":"Stage III(E)+B"},{"code":"IIIS","display":"Stage IIIS"},{"code":"IIIS+A","display":"Stage IIIS+A"},{"code":"IIIS+B","display":"Stage IIIS+B"},{"code":"III(S)","display":"Stage III(S)"},{"code":"III(S)+A","display":"Stage III(S)+A"},{"code":"III(S)+B","display":"Stage III(S)+B"},{"code":"IIIES","display":"Stage IIIES"},{"code":"IIIES+A","display":"Stage IIIES+A"},{"code":"IIIES+B","display":"Stage IIIES+B"},{"code":"III(E)S","display":"Stage III(E)S"},{"code":"III(E)S+A","display":"Stage III(E)S+A"},{"code":"III(E)S+B","display":"Stage III(E)S+B"},{"code":"IIIE(S)","display":"Stage IIIE(S)"},{"code":"IIIE(S)+A","display":"Stage IIIE(S)+A"},{"code":"IIIE(S)+B","display":"Stage IIIE(S)+B"},{"code":"III(E)(S)","display":"Stage III(E)(S)"},{"code":"III(E)(S)+A","display":"Stage III(E)(S)+A"},{"code":"III(E)(S)+B","display":"Stage III(E)(S)+B"},{"code":"IV","display":"Stage IV"},{"code":"IV+A","display":"Stage IV+A"},{"code":"IV+B","display":"Stage IV+B"}]}

package/CodeSystem-nkrs-basisoffirsttreatmentcomplexdecision.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-basisoffirsttreatmentcomplexdecision","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-basisoffirsttreatmentcomplexdecision defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-basisoffirsttreatmentcomplexdecision-1\"> </a></td><td>Tumour board</td><td>An interdisciplinary medical committee.</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-basisoffirsttreatmentcomplexdecision-2\"> </a></td><td>Other (not specified)</td><td>Not a tumour board.</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-basisoffirsttreatmentcomplexdecision","version":"0.9.0","name":"NkrsBasisOfFirstTreatmentComplexDecision","title":"NKRS - Basis of First Treatment Complex Decision","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"This data item records the basis of treatment decision for the entire first treatment complex. \r\nThe first treatment complex includes all therapy steps planned after the diagnosis. \r\n\r\n**Basis of first treatment complex decision (Variable number: 7.1)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"content":"complete","count":2,"concept":[{"code":"1","display":"Tumour board","definition":"An interdisciplinary medical committee."},{"code":"2","display":"Other (not specified)","definition":"Not a tumour board."}]}

package/CodeSystem-nkrs-binetstaging.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-binetstaging","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-binetstaging defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">A<a name=\"nkrs-binetstaging-A\"> </a></td><td>Stage A</td><td>Hb ≥ 10.0 g/dl, thrombocytes ≥100 × 109/l, &lt;3 lymph node regions.</td></tr><tr><td style=\"white-space:nowrap\">B<a name=\"nkrs-binetstaging-B\"> </a></td><td>Stage B</td><td>Hb ≥ 10.0 g/dl, thrombocytes ≥100 × 109/l, ≥3 lymph node regions.</td></tr><tr><td style=\"white-space:nowrap\">C<a name=\"nkrs-binetstaging-C\"> </a></td><td>Stage C</td><td>Hb &lt; 10.0 g/dl, thrombocytes &lt;100 × 109/l, any number of lymph node regions.</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-binetstaging","version":"0.9.0","name":"NkrsBinetStaging","title":"NKRS - Binet Staging","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"This data item records the stage of Chronic Lymphocytic Leukaemia (CLL) based on the cell count in the blood \r\nand bone marrow (lymphocytes, platelets), haemoglobin/ haematocrit, lymph nodes involvement, hepato- and/or splenomegaly. \r\n\r\n**Binet staging (Variable number: 4.27)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-binetstaging","content":"complete","count":3,"concept":[{"code":"A","display":"Stage A","definition":"Hb ≥ 10.0 g/dl, thrombocytes ≥100 × 109/l, <3 lymph node regions."},{"code":"B","display":"Stage B","definition":"Hb ≥ 10.0 g/dl, thrombocytes ≥100 × 109/l, ≥3 lymph node regions."},{"code":"C","display":"Stage C","definition":"Hb < 10.0 g/dl, thrombocytes <100 × 109/l, any number of lymph node regions."}]}

package/CodeSystem-nkrs-circumferentialresectionmargins.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-circumferentialresectionmargins","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-circumferentialresectionmargins defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-circumferentialresectionmargins-1\"> </a></td><td>0 mm</td><td>Positive, R1</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-circumferentialresectionmargins-2\"> </a></td><td>&lt;1 mm</td><td>Negative, R0 'close'</td></tr><tr><td style=\"white-space:nowrap\">3<a name=\"nkrs-circumferentialresectionmargins-3\"> </a></td><td>≥1 mm</td><td>Negative, R0 'wide'</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-circumferentialresectionmargins","version":"0.9.0","name":"NkrsCircumferentialResectionMargins","title":"NKRS - Circumferential Resection Margins","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The circumferential resection margin (CRM) is a surgically created plane produced during the removal of the rectum from its surroundings. \r\n\r\n**Circumferential resection margins (Variable number: 5.4.1)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-circumferentialresectionmargins","content":"complete","count":3,"concept":[{"code":"1","display":"0 mm","definition":"Positive, R1"},{"code":"2","display":"<1 mm","definition":"Negative, R0 'close'"},{"code":"3","display":"≥1 mm","definition":"Negative, R0 'wide'"}]}

package/CodeSystem-nkrs-cm.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-cm","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-cm defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">0<a name=\"nkrs-cm-0\"> </a></td><td>cM0</td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-cm-1\"> </a></td><td>cM1</td></tr><tr><td style=\"white-space:nowrap\">1a<a name=\"nkrs-cm-1a\"> </a></td><td>cM1a</td></tr><tr><td style=\"white-space:nowrap\">1a(0)<a name=\"nkrs-cm-1a.400.41\"> </a></td><td>cM1a(0)</td></tr><tr><td style=\"white-space:nowrap\">1a(1)<a name=\"nkrs-cm-1a.401.41\"> </a></td><td>cM1a(1)</td></tr><tr><td style=\"white-space:nowrap\">1b(0)<a name=\"nkrs-cm-1b.400.41\"> </a></td><td>cM1b(0)</td></tr><tr><td style=\"white-space:nowrap\">1b(1)<a name=\"nkrs-cm-1b.401.41\"> </a></td><td>cM1b(1)</td></tr><tr><td style=\"white-space:nowrap\">1c(0)<a name=\"nkrs-cm-1c.400.41\"> </a></td><td>cM1c(0)</td></tr><tr><td style=\"white-space:nowrap\">1c(1)<a name=\"nkrs-cm-1c.401.41\"> </a></td><td>cM1c(1)</td></tr><tr><td style=\"white-space:nowrap\">1d(0)<a name=\"nkrs-cm-1d.400.41\"> </a></td><td>cM1d(0)</td></tr><tr><td style=\"white-space:nowrap\">1d(1)<a name=\"nkrs-cm-1d.401.41\"> </a></td><td>cM1d(1)</td></tr><tr><td style=\"white-space:nowrap\">1b<a name=\"nkrs-cm-1b\"> </a></td><td>cM1b</td></tr><tr><td style=\"white-space:nowrap\">1c<a name=\"nkrs-cm-1c\"> </a></td><td>cM1c</td></tr><tr><td style=\"white-space:nowrap\">1d<a name=\"nkrs-cm-1d\"> </a></td><td>cM1d</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-cm","version":"0.9.0","name":"NkrscM","title":"NKRS - cM","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The data item records the absence or presence of distant metastases based on clinical investigation, imaging, endoscopy, surgical exploration without biopsy. \r\n\r\n**cM (Variable number: 4.5)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-cm","content":"complete","count":14,"concept":[{"code":"0","display":"cM0"},{"code":"1","display":"cM1"},{"code":"1a","display":"cM1a"},{"code":"1a(0)","display":"cM1a(0)"},{"code":"1a(1)","display":"cM1a(1)"},{"code":"1b(0)","display":"cM1b(0)"},{"code":"1b(1)","display":"cM1b(1)"},{"code":"1c(0)","display":"cM1c(0)"},{"code":"1c(1)","display":"cM1c(1)"},{"code":"1d(0)","display":"cM1d(0)"},{"code":"1d(1)","display":"cM1d(1)"},{"code":"1b","display":"cM1b"},{"code":"1c","display":"cM1c"},{"code":"1d","display":"cM1d"}]}

package/CodeSystem-nkrs-cn.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-cn","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-cn defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">X<a name=\"nkrs-cn-X\"> </a></td><td>cNX</td></tr><tr><td style=\"white-space:nowrap\">0<a name=\"nkrs-cn-0\"> </a></td><td>cN0</td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-cn-1\"> </a></td><td>cN1</td></tr><tr><td style=\"white-space:nowrap\">1a<a name=\"nkrs-cn-1a\"> </a></td><td>cN1a</td></tr><tr><td style=\"white-space:nowrap\">1b<a name=\"nkrs-cn-1b\"> </a></td><td>cN1b</td></tr><tr><td style=\"white-space:nowrap\">1c<a name=\"nkrs-cn-1c\"> </a></td><td>cN1c</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-cn-2\"> </a></td><td>cN2</td></tr><tr><td style=\"white-space:nowrap\">2a<a name=\"nkrs-cn-2a\"> </a></td><td>cN2a</td></tr><tr><td style=\"white-space:nowrap\">2b<a name=\"nkrs-cn-2b\"> </a></td><td>cN2b</td></tr><tr><td style=\"white-space:nowrap\">2c<a name=\"nkrs-cn-2c\"> </a></td><td>cN2c</td></tr><tr><td style=\"white-space:nowrap\">3<a name=\"nkrs-cn-3\"> </a></td><td>cN3</td></tr><tr><td style=\"white-space:nowrap\">3a<a name=\"nkrs-cn-3a\"> </a></td><td>cN3a</td></tr><tr><td style=\"white-space:nowrap\">3b<a name=\"nkrs-cn-3b\"> </a></td><td>cN3b</td></tr><tr><td style=\"white-space:nowrap\">3c<a name=\"nkrs-cn-3c\"> </a></td><td>cN3c</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-cn","version":"0.9.0","name":"NkrscN","title":"NKRS - cN","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The data item records regional lymph nodes involvement based on clinical investigation, imaging, endoscopy, biopsy or surgical exploration. \r\n\r\n**cN (Variable number: 4.4)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-cn","content":"complete","count":14,"concept":[{"code":"X","display":"cNX"},{"code":"0","display":"cN0"},{"code":"1","display":"cN1"},{"code":"1a","display":"cN1a"},{"code":"1b","display":"cN1b"},{"code":"1c","display":"cN1c"},{"code":"2","display":"cN2"},{"code":"2a","display":"cN2a"},{"code":"2b","display":"cN2b"},{"code":"2c","display":"cN2c"},{"code":"3","display":"cN3"},{"code":"3a","display":"cN3a"},{"code":"3b","display":"cN3b"},{"code":"3c","display":"cN3c"}]}

package/CodeSystem-nkrs-cogallstaging.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-cogallstaging","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-cogallstaging defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">CNS1<a name=\"nkrs-cogallstaging-CNS1\"> </a></td><td>CNS1</td><td>No blasts in the CSF, regardless of WBC and RBC.</td></tr><tr><td style=\"white-space:nowrap\">CNS2<a name=\"nkrs-cogallstaging-CNS2\"> </a></td><td>CNS2</td><td>CNS2, not otherwise specified</td></tr><tr><td style=\"white-space:nowrap\">CNS2a<a name=\"nkrs-cogallstaging-CNS2a\"> </a></td><td>CNS2a</td><td>&lt;5 WBC/µL + blasts + &lt;10 RBC/µL.</td></tr><tr><td style=\"white-space:nowrap\">CNS2b<a name=\"nkrs-cogallstaging-CNS2b\"> </a></td><td>CNS2b</td><td>&lt;5 WBC/µL + blasts + ≥10 RBC/µL</td></tr><tr><td style=\"white-space:nowrap\">CNS2c<a name=\"nkrs-cogallstaging-CNS2c\"> </a></td><td>CNS2c</td><td>≥5 WBC/µL + blasts + ≥10 RBC/µL, excess WBC proportional to RBC</td></tr><tr><td style=\"white-space:nowrap\">CNS3<a name=\"nkrs-cogallstaging-CNS3\"> </a></td><td>CNS3</td><td>CNS3, not otherwise specified</td></tr><tr><td style=\"white-space:nowrap\">CNS3a<a name=\"nkrs-cogallstaging-CNS3a\"> </a></td><td>CNS3a</td><td>≥5 WBC/µL + blasts + &lt;10 RBC/µL</td></tr><tr><td style=\"white-space:nowrap\">CNS3b<a name=\"nkrs-cogallstaging-CNS3b\"> </a></td><td>CNS3b</td><td>≥5 WBC/µL + blasts + ≥10 RBC/µL, excess WBC not proportional to RBC</td></tr><tr><td style=\"white-space:nowrap\">CNS3c<a name=\"nkrs-cogallstaging-CNS3c\"> </a></td><td>CNS3c</td><td>Clinical signs of CNS involvement.</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-cogallstaging","version":"0.9.0","name":"NkrsCOGALLStaging","title":"NKRS - COG ALL Staging","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"COG ALL staging (for childhood B- precursor acute lymphoblastic leukemia, B-ALL) allows a uniform assessment \r\nof the extent of CNS involvement based on presence of blasts in the diagnostic cerebrospinal fluid (CSF). \r\n\r\n**COG ALL staging (Variable number: 4.20)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-cogallstaging","content":"complete","count":9,"concept":[{"code":"CNS1","display":"CNS1","definition":"No blasts in the CSF, regardless of WBC and RBC."},{"code":"CNS2","display":"CNS2","definition":"CNS2, not otherwise specified"},{"code":"CNS2a","display":"CNS2a","definition":"<5 WBC/µL + blasts + <10 RBC/µL."},{"code":"CNS2b","display":"CNS2b","definition":"<5 WBC/µL + blasts + ≥10 RBC/µL"},{"code":"CNS2c","display":"CNS2c","definition":"≥5 WBC/µL + blasts + ≥10 RBC/µL, excess WBC proportional to RBC"},{"code":"CNS3","display":"CNS3","definition":"CNS3, not otherwise specified"},{"code":"CNS3a","display":"CNS3a","definition":"≥5 WBC/µL + blasts + <10 RBC/µL"},{"code":"CNS3b","display":"CNS3b","definition":"≥5 WBC/µL + blasts + ≥10 RBC/µL, excess WBC not proportional to RBC"},{"code":"CNS3c","display":"CNS3c","definition":"Clinical signs of CNS involvement."}]}

package/CodeSystem-nkrs-cogstaging.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-cogstaging","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-cogstaging defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">I<a name=\"nkrs-cogstaging-I\"> </a></td><td>Stage I</td><td>Limited to kidney, not ruptured, no residual tumor.</td></tr><tr><td style=\"white-space:nowrap\">II<a name=\"nkrs-cogstaging-II\"> </a></td><td>Stage II</td><td>Extends beyond the kidney but is completely excised.</td></tr><tr><td style=\"white-space:nowrap\">III<a name=\"nkrs-cogstaging-III\"> </a></td><td>Stage III</td><td>Residual tumor confined to the abdomen. Micro/macroscopic remains of a tumour.</td></tr><tr><td style=\"white-space:nowrap\">IV<a name=\"nkrs-cogstaging-IV\"> </a></td><td>Stage IV</td><td>Hematogenous / distant lymph nodes metastases.</td></tr><tr><td style=\"white-space:nowrap\">V<a name=\"nkrs-cogstaging-V\"> </a></td><td>Stage V</td><td>Bilateral renal involvement at diagnosis.</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-cogstaging","version":"0.9.0","name":"NkrsCOGStaging","title":"NKRS - COG Staging","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"This data item records staging of Wilms’ tumour for pediatric patients acc. to pre-chemotherapy staging \r\nsystem developed by the National Wilms’ Tumor Study Group (NWTSG). Based exclusively on the anatomic extent of the \r\ntumour, without consideration of genetic, biologic, or molecular markers. \r\n\r\n**COG staging (Variable number: 4.19)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-cogstaging","content":"complete","count":5,"concept":[{"code":"I","display":"Stage I","definition":"Limited to kidney, not ruptured, no residual tumor."},{"code":"II","display":"Stage II","definition":"Extends beyond the kidney but is completely excised."},{"code":"III","display":"Stage III","definition":"Residual tumor confined to the abdomen. Micro/macroscopic remains of a tumour."},{"code":"IV","display":"Stage IV","definition":"Hematogenous / distant lymph nodes metastases."},{"code":"V","display":"Stage V","definition":"Bilateral renal involvement at diagnosis."}]}

package/CodeSystem-nkrs-creasmangradingsystem.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-creasmangradingsystem","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-creasmangradingsystem defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-creasmangradingsystem-1\"> </a></td><td>G1</td><td>≤5% of a nonsquamous or nonmorular solid growth pattern</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-creasmangradingsystem-2\"> </a></td><td>G2</td><td>6−50% of a nonsquamous or nonmorular solid growth pattern</td></tr><tr><td style=\"white-space:nowrap\">3<a name=\"nkrs-creasmangradingsystem-3\"> </a></td><td>G3</td><td>&gt;50% of a nonsquamous or nonmorular solid growth pattern</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-creasmangradingsystem","version":"0.9.0","name":"NkrsCreasmanGradingSystem","title":"NKRS - Creasman Grading System","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"This data item records histopathological grade for uterine or endometrial cancer. \r\n\r\n**Creasman grading system (Variable number: 4.34)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-creasmangradingsystem","content":"complete","count":3,"concept":[{"code":"1","display":"G1","definition":"≤5% of a nonsquamous or nonmorular solid growth pattern"},{"code":"2","display":"G2","definition":"6−50% of a nonsquamous or nonmorular solid growth pattern"},{"code":"3","display":"G3","definition":">50% of a nonsquamous or nonmorular solid growth pattern"}]}

package/CodeSystem-nkrs-ct.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-ct","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-ct defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">X<a name=\"nkrs-ct-X\"> </a></td><td>cTX</td></tr><tr><td style=\"white-space:nowrap\">0<a name=\"nkrs-ct-0\"> </a></td><td>cT0</td></tr><tr><td style=\"white-space:nowrap\">a<a name=\"nkrs-ct-a\"> </a></td><td>cTa</td></tr><tr><td style=\"white-space:nowrap\">is<a name=\"nkrs-ct-is\"> </a></td><td>cTis</td></tr><tr><td style=\"white-space:nowrap\">is(LAMN)<a name=\"nkrs-ct-is.40LAMN.41\"> </a></td><td>cTisLAMN</td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-ct-1\"> </a></td><td>cT1</td></tr><tr><td style=\"white-space:nowrap\">1a<a name=\"nkrs-ct-1a\"> </a></td><td>cT1a</td></tr><tr><td style=\"white-space:nowrap\">1a1<a name=\"nkrs-ct-1a1\"> </a></td><td>cT1a1</td></tr><tr><td style=\"white-space:nowrap\">1a2<a name=\"nkrs-ct-1a2\"> </a></td><td>cT1a2</td></tr><tr><td style=\"white-space:nowrap\">1b<a name=\"nkrs-ct-1b\"> </a></td><td>cT1b</td></tr><tr><td style=\"white-space:nowrap\">1b1<a name=\"nkrs-ct-1b1\"> </a></td><td>cT1b1</td></tr><tr><td style=\"white-space:nowrap\">1b2<a name=\"nkrs-ct-1b2\"> </a></td><td>cT1b2</td></tr><tr><td style=\"white-space:nowrap\">1c<a name=\"nkrs-ct-1c\"> </a></td><td>cT1c</td></tr><tr><td style=\"white-space:nowrap\">1c1<a name=\"nkrs-ct-1c1\"> </a></td><td>cT1c1</td></tr><tr><td style=\"white-space:nowrap\">1c2<a name=\"nkrs-ct-1c2\"> </a></td><td>cT1c2</td></tr><tr><td style=\"white-space:nowrap\">1c3<a name=\"nkrs-ct-1c3\"> </a></td><td>cT1c3</td></tr><tr><td style=\"white-space:nowrap\">1d<a name=\"nkrs-ct-1d\"> </a></td><td>cT1d</td></tr><tr><td style=\"white-space:nowrap\">1m1<a name=\"nkrs-ct-1m1\"> </a></td><td>cT1mi</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-ct-2\"> </a></td><td>cT2</td></tr><tr><td style=\"white-space:nowrap\">2a<a name=\"nkrs-ct-2a\"> </a></td><td>cT2a</td></tr><tr><td style=\"white-space:nowrap\">2a1<a name=\"nkrs-ct-2a1\"> </a></td><td>cT2a1</td></tr><tr><td style=\"white-space:nowrap\">2a2<a name=\"nkrs-ct-2a2\"> </a></td><td>cT2a2</td></tr><tr><td style=\"white-space:nowrap\">2b<a name=\"nkrs-ct-2b\"> </a></td><td>cT2b</td></tr><tr><td style=\"white-space:nowrap\">2c<a name=\"nkrs-ct-2c\"> </a></td><td>cT2c</td></tr><tr><td style=\"white-space:nowrap\">2d<a name=\"nkrs-ct-2d\"> </a></td><td>cT2d</td></tr><tr><td style=\"white-space:nowrap\">3<a name=\"nkrs-ct-3\"> </a></td><td>cT3</td></tr><tr><td style=\"white-space:nowrap\">3a<a name=\"nkrs-ct-3a\"> </a></td><td>cT3a</td></tr><tr><td style=\"white-space:nowrap\">3b<a name=\"nkrs-ct-3b\"> </a></td><td>cT3b</td></tr><tr><td style=\"white-space:nowrap\">3c<a name=\"nkrs-ct-3c\"> </a></td><td>cT3c</td></tr><tr><td style=\"white-space:nowrap\">3d<a name=\"nkrs-ct-3d\"> </a></td><td>cT3d</td></tr><tr><td style=\"white-space:nowrap\">3e<a name=\"nkrs-ct-3e\"> </a></td><td>cT3e</td></tr><tr><td style=\"white-space:nowrap\">4<a name=\"nkrs-ct-4\"> </a></td><td>cT4</td></tr><tr><td style=\"white-space:nowrap\">4a<a name=\"nkrs-ct-4a\"> </a></td><td>cT4a</td></tr><tr><td style=\"white-space:nowrap\">4b<a name=\"nkrs-ct-4b\"> </a></td><td>cT4b</td></tr><tr><td style=\"white-space:nowrap\">4c<a name=\"nkrs-ct-4c\"> </a></td><td>cT4c</td></tr><tr><td style=\"white-space:nowrap\">4d<a name=\"nkrs-ct-4d\"> </a></td><td>cT4d</td></tr><tr><td style=\"white-space:nowrap\">4e<a name=\"nkrs-ct-4e\"> </a></td><td>cT4e</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-ct","version":"0.9.0","name":"NkrscT","title":"NKRS - cT","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The data item records tumour size based on clinical investigation, imaging, endoscopy, biopsy or surgical exploration. \r\n\r\n**cT (Variable number: 4.3)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-ct","content":"complete","count":37,"concept":[{"code":"X","display":"cTX"},{"code":"0","display":"cT0"},{"code":"a","display":"cTa"},{"code":"is","display":"cTis"},{"code":"is(LAMN)","display":"cTisLAMN"},{"code":"1","display":"cT1"},{"code":"1a","display":"cT1a"},{"code":"1a1","display":"cT1a1"},{"code":"1a2","display":"cT1a2"},{"code":"1b","display":"cT1b"},{"code":"1b1","display":"cT1b1"},{"code":"1b2","display":"cT1b2"},{"code":"1c","display":"cT1c"},{"code":"1c1","display":"cT1c1"},{"code":"1c2","display":"cT1c2"},{"code":"1c3","display":"cT1c3"},{"code":"1d","display":"cT1d"},{"code":"1m1","display":"cT1mi"},{"code":"2","display":"cT2"},{"code":"2a","display":"cT2a"},{"code":"2a1","display":"cT2a1"},{"code":"2a2","display":"cT2a2"},{"code":"2b","display":"cT2b"},{"code":"2c","display":"cT2c"},{"code":"2d","display":"cT2d"},{"code":"3","display":"cT3"},{"code":"3a","display":"cT3a"},{"code":"3b","display":"cT3b"},{"code":"3c","display":"cT3c"},{"code":"3d","display":"cT3d"},{"code":"3e","display":"cT3e"},{"code":"4","display":"cT4"},{"code":"4a","display":"cT4a"},{"code":"4b","display":"cT4b"},{"code":"4c","display":"cT4c"},{"code":"4d","display":"cT4d"},{"code":"4e","display":"cT4e"}]}

package/CodeSystem-nkrs-diabetesmellitus.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-diabetesmellitus","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-diabetesmellitus defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">0<a name=\"nkrs-diabetesmellitus-0\"> </a></td><td>No (score 0)</td><td>Inclusive: \r\nDiabetes during pregnancy alone (ICD-10: O24.0-9) / \r\nDiabetes treated with diet alone / \r\nOther endocrines like hypopituitarism, adrenal insufficiency, and recurrent acidosis (ICD-10: E20-E35)</td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-diabetesmellitus-1\"> </a></td><td>Uncomplicated (score 1)</td><td>Inclusive all patients \r\ndiagnosed with diabetes AND \r\ntreated with insulin or oral hypoglycaemic, but not diet alone \r\n(ICD-10: E10.0, E10.1, E10.6, E10.8, E10.9, E11.0, E11.1, E11.6, E11.8, E11.9, E12.0, E12.1, E12.6, E12.8, E12.9, E13.0, E13.1, E13.6, E13.8, E13.9, E14.0, E14.1, E14.6, E14.8, E14.9)</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-diabetesmellitus-2\"> </a></td><td>End-organ damage (score 2)</td><td>End organ damage can include retinopathy AND/OR neuropathy AND/OR nephropathy attributable to diabetes \r\n(ICD-10: E10.2–E10.5, E10.7, E11.2–E11.5, E11.7, E12.2–E12.5, E12.7, E13.2–E13.5, E13.7, E14.2–E14.5, E14.7)</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-diabetesmellitus","version":"0.9.0","name":"NkrsDiabetesMellitus","title":"NKRS - Diabetes Mellitus","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The data item records the presence and severity of diabetes mellitus at the time of diagnosis \r\nas pre-existing medical condition. Scores weight the estimated effect on patient survival. \r\n\r\n**Diabetes mellitus (Variable number: 10.1)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part B1, SUPPLEMENTARY VARIABLES for Adults (15.10.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/b1-datadictionary-supplementaryvariables-adults-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/variablen-zusatzdaten-kinderjugendliche-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/b1-dict-des-donnees-variables-suppl-adultes-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/b1-variabili-supplementari-adulti-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-diabetesmellitus","content":"complete","count":3,"concept":[{"code":"0","display":"No (score 0)","definition":"Inclusive: \r\nDiabetes during pregnancy alone (ICD-10: O24.0-9) / \r\nDiabetes treated with diet alone / \r\nOther endocrines like hypopituitarism, adrenal insufficiency, and recurrent acidosis (ICD-10: E20-E35)"},{"code":"1","display":"Uncomplicated (score 1)","definition":"Inclusive all patients \r\ndiagnosed with diabetes AND \r\ntreated with insulin or oral hypoglycaemic, but not diet alone \r\n(ICD-10: E10.0, E10.1, E10.6, E10.8, E10.9, E11.0, E11.1, E11.6, E11.8, E11.9, E12.0, E12.1, E12.6, E12.8, E12.9, E13.0, E13.1, E13.6, E13.8, E13.9, E14.0, E14.1, E14.6, E14.8, E14.9)"},{"code":"2","display":"End-organ damage (score 2)","definition":"End organ damage can include retinopathy AND/OR neuropathy AND/OR nephropathy attributable to diabetes \r\n(ICD-10: E10.2–E10.5, E10.7, E11.2–E11.5, E11.7, E12.2–E12.5, E12.7, E13.2–E13.5, E13.7, E14.2–E14.5, E14.7)"}]}

package/CodeSystem-nkrs-diagnosticmethodsused.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-diagnosticmethodsused","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-diagnosticmethodsused defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">0<a name=\"nkrs-diagnosticmethodsused-0\"> </a></td><td>Death certificate notification</td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-diagnosticmethodsused-1\"> </a></td><td>Clinical examination undefined</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-diagnosticmethodsused-2\"> </a></td><td>Clinical examination defined</td></tr><tr><td style=\"white-space:nowrap\">3<a name=\"nkrs-diagnosticmethodsused-3\"> </a></td><td>Tumour clinically palpable</td></tr><tr><td style=\"white-space:nowrap\">4<a name=\"nkrs-diagnosticmethodsused-4\"> </a></td><td>Radiodiagnostic of tumour (Xray)</td></tr><tr><td style=\"white-space:nowrap\">5<a name=\"nkrs-diagnosticmethodsused-5\"> </a></td><td>Echography of tumour (ultrasound, sonography)</td></tr><tr><td style=\"white-space:nowrap\">6<a name=\"nkrs-diagnosticmethodsused-6\"> </a></td><td>Scintigraphy of tumour (e.g. MIBG)</td></tr><tr><td style=\"white-space:nowrap\">7<a name=\"nkrs-diagnosticmethodsused-7\"> </a></td><td>CT scan of tumour</td></tr><tr><td style=\"white-space:nowrap\">8<a name=\"nkrs-diagnosticmethodsused-8\"> </a></td><td>MRI scan of tumour</td></tr><tr><td style=\"white-space:nowrap\">9<a name=\"nkrs-diagnosticmethodsused-9\"> </a></td><td>Specific imaging of tumour (e.g. PET/CT, SPECT, fluorescent optical imaging)</td></tr><tr><td style=\"white-space:nowrap\">10<a name=\"nkrs-diagnosticmethodsused-10\"> </a></td><td>Imaging to determine spread of disease (metastases)</td></tr><tr><td style=\"white-space:nowrap\">11<a name=\"nkrs-diagnosticmethodsused-11\"> </a></td><td>Endoscopy</td></tr><tr><td style=\"white-space:nowrap\">12<a name=\"nkrs-diagnosticmethodsused-12\"> </a></td><td>Imaging NOS</td></tr><tr><td style=\"white-space:nowrap\">13<a name=\"nkrs-diagnosticmethodsused-13\"> </a></td><td>Specific markers ( biochemical or immunological)</td></tr><tr><td style=\"white-space:nowrap\">14<a name=\"nkrs-diagnosticmethodsused-14\"> </a></td><td>Cytogenetic analysis (karyotype)</td></tr><tr><td style=\"white-space:nowrap\">15<a name=\"nkrs-diagnosticmethodsused-15\"> </a></td><td>Molecular markers (FISH, SNP, MLPA, PCR, DNA sequence etc.)</td></tr><tr><td style=\"white-space:nowrap\">16<a name=\"nkrs-diagnosticmethodsused-16\"> </a></td><td>Cytology NOS / Blood smear / peripheral blood</td></tr><tr><td style=\"white-space:nowrap\">17<a name=\"nkrs-diagnosticmethodsused-17\"> </a></td><td>Cytology of tumour (e.g. fine needle aspirate/ PAP)</td></tr><tr><td style=\"white-space:nowrap\">18<a name=\"nkrs-diagnosticmethodsused-18\"> </a></td><td>Bone marrow aspirate</td></tr><tr><td style=\"white-space:nowrap\">19<a name=\"nkrs-diagnosticmethodsused-19\"> </a></td><td>Bone marrow biopsy</td></tr><tr><td style=\"white-space:nowrap\">20<a name=\"nkrs-diagnosticmethodsused-20\"> </a></td><td>Biopsy unspecified</td></tr><tr><td style=\"white-space:nowrap\">21<a name=\"nkrs-diagnosticmethodsused-21\"> </a></td><td>Biopsy locoregional</td></tr><tr><td style=\"white-space:nowrap\">22<a name=\"nkrs-diagnosticmethodsused-22\"> </a></td><td>Biopsy of metastasis</td></tr><tr><td style=\"white-space:nowrap\">23<a name=\"nkrs-diagnosticmethodsused-23\"> </a></td><td>Biopsy locoregional or of metastasis</td></tr><tr><td style=\"white-space:nowrap\">24<a name=\"nkrs-diagnosticmethodsused-24\"> </a></td><td>Biopsy of primary tumour</td></tr><tr><td style=\"white-space:nowrap\">25<a name=\"nkrs-diagnosticmethodsused-25\"> </a></td><td>Biopsy and resection (z.B. melanoma)</td></tr><tr><td style=\"white-space:nowrap\">26<a name=\"nkrs-diagnosticmethodsused-26\"> </a></td><td>Surgical tissue from operation (e.g. neuroendocrine tumours)</td></tr><tr><td style=\"white-space:nowrap\">27<a name=\"nkrs-diagnosticmethodsused-27\"> </a></td><td>Autopsy with histological confirmation</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-diagnosticmethodsused","version":"0.9.0","name":"NkrsDiagnosticMethodsUsed","title":"NKRS - Diagnostic Methods Used","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The data item records all diagnostic methods used. \r\n\r\n**Diagnostic method(s) used (Variable number: 2.8)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-diagnosticmethodsused","content":"complete","count":28,"concept":[{"code":"0","display":"Death certificate notification"},{"code":"1","display":"Clinical examination undefined"},{"code":"2","display":"Clinical examination defined"},{"code":"3","display":"Tumour clinically palpable"},{"code":"4","display":"Radiodiagnostic of tumour (Xray)"},{"code":"5","display":"Echography of tumour (ultrasound, sonography)"},{"code":"6","display":"Scintigraphy of tumour (e.g. MIBG)"},{"code":"7","display":"CT scan of tumour"},{"code":"8","display":"MRI scan of tumour"},{"code":"9","display":"Specific imaging of tumour (e.g. PET/CT, SPECT, fluorescent optical imaging)"},{"code":"10","display":"Imaging to determine spread of disease (metastases)"},{"code":"11","display":"Endoscopy"},{"code":"12","display":"Imaging NOS"},{"code":"13","display":"Specific markers ( biochemical or immunological)"},{"code":"14","display":"Cytogenetic analysis (karyotype)"},{"code":"15","display":"Molecular markers (FISH, SNP, MLPA, PCR, DNA sequence etc.)"},{"code":"16","display":"Cytology NOS / Blood smear / peripheral blood"},{"code":"17","display":"Cytology of tumour (e.g. fine needle aspirate/ PAP)"},{"code":"18","display":"Bone marrow aspirate"},{"code":"19","display":"Bone marrow biopsy"},{"code":"20","display":"Biopsy unspecified"},{"code":"21","display":"Biopsy locoregional"},{"code":"22","display":"Biopsy of metastasis"},{"code":"23","display":"Biopsy locoregional or of metastasis"},{"code":"24","display":"Biopsy of primary tumour"},{"code":"25","display":"Biopsy and resection (z.B. melanoma)"},{"code":"26","display":"Surgical tissue from operation (e.g. neuroendocrine tumours)"},{"code":"27","display":"Autopsy with histological confirmation"}]}

package/CodeSystem-nkrs-dssplus.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-dssplus","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-dssplus defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">IA<a name=\"nkrs-dssplus-IA\"> </a></td><td>Stage IA</td><td>Smoldering or indolent. Can have single plasmocytoma or limited disease at imaging; Normal renal function (serum creatinine level &lt; 2.0 mg/dL).</td></tr><tr><td style=\"white-space:nowrap\">IB<a name=\"nkrs-dssplus-IB\"> </a></td><td>Stage IB</td><td>&lt; 5 focal lesions, mild diffuse disease; Abnormal renal function (serum creatinine level ≥ 2.0 mg/dL).</td></tr><tr><td style=\"white-space:nowrap\">IIA<a name=\"nkrs-dssplus-IIA\"> </a></td><td>Stage IIA</td><td>5–20 focal lesions; moderate diffuse disease; Normal renal function (serum creatinine level &lt; 2.0 mg/dL).</td></tr><tr><td style=\"white-space:nowrap\">IIB<a name=\"nkrs-dssplus-IIB\"> </a></td><td>Stage IIB</td><td>5–20 focal lesions; moderate diffuse disease; Abnormal renal function (serum creatinine level ≥ 2.0 mg/dL).</td></tr><tr><td style=\"white-space:nowrap\">IIIA<a name=\"nkrs-dssplus-IIIA\"> </a></td><td>Stage IIIA</td><td>&gt; 20 focal lesions; moderate diffuse disease; normal renal function (serum creatinine level &lt; 2.0 mg/dL).</td></tr><tr><td style=\"white-space:nowrap\">IIIB<a name=\"nkrs-dssplus-IIIB\"> </a></td><td>Stage IIIB</td><td>&gt; 20 focal lesions; moderate diffuse disease; Abnormal renal function (serum creatinine level ≥ 2.0 mg/dL).</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-dssplus","version":"0.9.0","name":"NkrsDSSplus","title":"NKRS - DSSplus","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The DSSplus (Durie-Salmon Plus staging system) is the revised Durie-Salmon staging system for multiple myeloma \r\nclassification, based on MRI findings, FDG PET/CT findings, or both. \r\n\r\n**DSSplus (Variable number: 4.30)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-dssplus","content":"complete","count":6,"concept":[{"code":"IA","display":"Stage IA","definition":"Smoldering or indolent. Can have single plasmocytoma or limited disease at imaging; Normal renal function (serum creatinine level < 2.0 mg/dL)."},{"code":"IB","display":"Stage IB","definition":"< 5 focal lesions, mild diffuse disease; Abnormal renal function (serum creatinine level ≥ 2.0 mg/dL)."},{"code":"IIA","display":"Stage IIA","definition":"5–20 focal lesions; moderate diffuse disease; Normal renal function (serum creatinine level < 2.0 mg/dL)."},{"code":"IIB","display":"Stage IIB","definition":"5–20 focal lesions; moderate diffuse disease; Abnormal renal function (serum creatinine level ≥ 2.0 mg/dL)."},{"code":"IIIA","display":"Stage IIIA","definition":"> 20 focal lesions; moderate diffuse disease; normal renal function (serum creatinine level < 2.0 mg/dL)."},{"code":"IIIB","display":"Stage IIIB","definition":"> 20 focal lesions; moderate diffuse disease; Abnormal renal function (serum creatinine level ≥ 2.0 mg/dL)."}]}

package/CodeSystem-nkrs-elstonellisgradingsystem.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-elstonellisgradingsystem","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-elstonellisgradingsystem defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-elstonellisgradingsystem-1\"> </a></td><td>grade I</td><td>well-differentiated</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-elstonellisgradingsystem-2\"> </a></td><td>grade II</td><td>moderately differentiated</td></tr><tr><td style=\"white-space:nowrap\">3<a name=\"nkrs-elstonellisgradingsystem-3\"> </a></td><td>grade III</td><td>poorly differentiated</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-elstonellisgradingsystem","version":"0.9.0","name":"NkrsElstonEllisGradingSystem","title":"NKRS - Elston/Ellis Grading System","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"This data item records the histopathological grade for breast cancer. It is also called the Nottingham \r\nHistological Score. The grade for an individual tumour is derived from an assessment of three morphological features \r\n(Tubule formation, Nuclear pleomorphism, Mitotic count), each of which is scored 1-3. \r\n\r\n**Elston/Ellis grading system (Variable number: 4.35)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-elstonellisgradingsystem","content":"complete","count":3,"concept":[{"code":"1","display":"grade I","definition":"well-differentiated"},{"code":"2","display":"grade II","definition":"moderately differentiated"},{"code":"3","display":"grade III","definition":"poorly differentiated"}]}

package/CodeSystem-nkrs-figostaging.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-figostaging","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-figostaging defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">I<a name=\"nkrs-figostaging-I\"> </a></td><td>Stage I</td></tr><tr><td style=\"white-space:nowrap\">IA<a name=\"nkrs-figostaging-IA\"> </a></td><td>Stage IA</td></tr><tr><td style=\"white-space:nowrap\">IA1<a name=\"nkrs-figostaging-IA1\"> </a></td><td>Stage IA1</td></tr><tr><td style=\"white-space:nowrap\">IA2<a name=\"nkrs-figostaging-IA2\"> </a></td><td>Stage IA2</td></tr><tr><td style=\"white-space:nowrap\">IB<a name=\"nkrs-figostaging-IB\"> </a></td><td>Stage IB</td></tr><tr><td style=\"white-space:nowrap\">IB1<a name=\"nkrs-figostaging-IB1\"> </a></td><td>Stage IB1</td></tr><tr><td style=\"white-space:nowrap\">IB2<a name=\"nkrs-figostaging-IB2\"> </a></td><td>Stage IB2</td></tr><tr><td style=\"white-space:nowrap\">IC<a name=\"nkrs-figostaging-IC\"> </a></td><td>Stage IC</td></tr><tr><td style=\"white-space:nowrap\">IC1<a name=\"nkrs-figostaging-IC1\"> </a></td><td>Stage IC1</td></tr><tr><td style=\"white-space:nowrap\">IC2<a name=\"nkrs-figostaging-IC2\"> </a></td><td>Stage IC2</td></tr><tr><td style=\"white-space:nowrap\">IC3<a name=\"nkrs-figostaging-IC3\"> </a></td><td>Stage IC3</td></tr><tr><td style=\"white-space:nowrap\">II<a name=\"nkrs-figostaging-II\"> </a></td><td>Stage II</td></tr><tr><td style=\"white-space:nowrap\">IIA<a name=\"nkrs-figostaging-IIA\"> </a></td><td>Stage IIA</td></tr><tr><td style=\"white-space:nowrap\">IIA1<a name=\"nkrs-figostaging-IIA1\"> </a></td><td>Stage IIA1</td></tr><tr><td style=\"white-space:nowrap\">IIA2<a name=\"nkrs-figostaging-IIA2\"> </a></td><td>Stage IIA2</td></tr><tr><td style=\"white-space:nowrap\">IIB<a name=\"nkrs-figostaging-IIB\"> </a></td><td>Stage IIB</td></tr><tr><td style=\"white-space:nowrap\">IIC<a name=\"nkrs-figostaging-IIC\"> </a></td><td>Stage IIC</td></tr><tr><td style=\"white-space:nowrap\">III<a name=\"nkrs-figostaging-III\"> </a></td><td>Stage III</td></tr><tr><td style=\"white-space:nowrap\">IIIA<a name=\"nkrs-figostaging-IIIA\"> </a></td><td>Stage IIIA</td></tr><tr><td style=\"white-space:nowrap\">IIIA1i<a name=\"nkrs-figostaging-IIIA1i\"> </a></td><td>Stage IIIA1i</td></tr><tr><td style=\"white-space:nowrap\">IIIA1ii<a name=\"nkrs-figostaging-IIIA1ii\"> </a></td><td>Stage IIIA1ii</td></tr><tr><td style=\"white-space:nowrap\">IIIA2<a name=\"nkrs-figostaging-IIIA2\"> </a></td><td>Stage IIIA2</td></tr><tr><td style=\"white-space:nowrap\">IIIB<a name=\"nkrs-figostaging-IIIB\"> </a></td><td>Stage IIIB</td></tr><tr><td style=\"white-space:nowrap\">IIIC<a name=\"nkrs-figostaging-IIIC\"> </a></td><td>Stage IIIC</td></tr><tr><td style=\"white-space:nowrap\">IIIC1<a name=\"nkrs-figostaging-IIIC1\"> </a></td><td>Stage IIIC1</td></tr><tr><td style=\"white-space:nowrap\">IIIC2<a name=\"nkrs-figostaging-IIIC2\"> </a></td><td>Stage IIIC2</td></tr><tr><td style=\"white-space:nowrap\">IV<a name=\"nkrs-figostaging-IV\"> </a></td><td>Stage IV</td></tr><tr><td style=\"white-space:nowrap\">IVA<a name=\"nkrs-figostaging-IVA\"> </a></td><td>Stage IVA</td></tr><tr><td style=\"white-space:nowrap\">IVB<a name=\"nkrs-figostaging-IVB\"> </a></td><td>Stage IVB</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-figostaging","version":"0.9.0","name":"NkrsFIGOStaging","title":"NKRS - FIGO Staging","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"FIGO Staging of gynecologic tumours is based on clinical staging, careful clinical \r\nexamination before therapy, and surgical exploration. \r\n\r\n**FIGO staging (Variable number: 4.21)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.2, Part A, BASIC VARIABLES for Adults, Adolescents, and Children\\'","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-figostaging","content":"complete","count":29,"concept":[{"code":"I","display":"Stage I"},{"code":"IA","display":"Stage IA"},{"code":"IA1","display":"Stage IA1"},{"code":"IA2","display":"Stage IA2"},{"code":"IB","display":"Stage IB"},{"code":"IB1","display":"Stage IB1"},{"code":"IB2","display":"Stage IB2"},{"code":"IC","display":"Stage IC"},{"code":"IC1","display":"Stage IC1"},{"code":"IC2","display":"Stage IC2"},{"code":"IC3","display":"Stage IC3"},{"code":"II","display":"Stage II"},{"code":"IIA","display":"Stage IIA"},{"code":"IIA1","display":"Stage IIA1"},{"code":"IIA2","display":"Stage IIA2"},{"code":"IIB","display":"Stage IIB"},{"code":"IIC","display":"Stage IIC"},{"code":"III","display":"Stage III"},{"code":"IIIA","display":"Stage IIIA"},{"code":"IIIA1i","display":"Stage IIIA1i"},{"code":"IIIA1ii","display":"Stage IIIA1ii"},{"code":"IIIA2","display":"Stage IIIA2"},{"code":"IIIB","display":"Stage IIIB"},{"code":"IIIC","display":"Stage IIIC"},{"code":"IIIC1","display":"Stage IIIC1"},{"code":"IIIC2","display":"Stage IIIC2"},{"code":"IV","display":"Stage IV"},{"code":"IVA","display":"Stage IVA"},{"code":"IVB","display":"Stage IVB"}]}

package/CodeSystem-nkrs-hcg.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-hcg","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-hcg defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">0<a name=\"nkrs-hcg-0\"> </a></td><td>hCG0</td><td>Within reference range</td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-hcg-1\"> </a></td><td>hCG1</td><td>&gt; upper limit of reference range if upper limit &lt; 5’000 mIU/ml</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-hcg-2\"> </a></td><td>hCG2</td><td>5’000 – 50’000 mIU/ml</td></tr><tr><td style=\"white-space:nowrap\">3<a name=\"nkrs-hcg-3\"> </a></td><td>hCG3</td><td>&gt; 50’000 mIU/ml</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-hcg","version":"0.9.0","name":"NkrsHCG","title":"NKRS - β-hCG","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The data item records the level of serum tumour marker human chorionic gonadotropin (β-hCG). \r\n\r\n**β-hCG (Variable number: 5.5.2)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-betahcg","content":"complete","count":4,"concept":[{"code":"0","display":"hCG0","definition":"Within reference range"},{"code":"1","display":"hCG1","definition":"> upper limit of reference range if upper limit < 5’000 mIU/ml"},{"code":"2","display":"hCG2","definition":"5’000 – 50’000 mIU/ml"},{"code":"3","display":"hCG3","definition":"> 50’000 mIU/ml"}]}

package/CodeSystem-nkrs-her2receptorstatus.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-her2receptorstatus","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-her2receptorstatus defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-her2receptorstatus-1\"> </a></td><td>Her2 overexpressed or gene amplified</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-her2receptorstatus-2\"> </a></td><td>Her2 not overexpressed or gene not amplified</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-her2receptorstatus","version":"0.9.0","name":"NkrsHer2ReceptorStatus","title":"NKRS - Her2 Receptor Status","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The data item records the Her2 (human epidermal growth factor receptor 2) expression status of the tumour. \r\n\r\n**Her2 receptor status (Variable number: 5.1.3)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-her2receptorstatus","content":"complete","count":2,"concept":[{"code":"1","display":"Her2 overexpressed or gene amplified"},{"code":"2","display":"Her2 not overexpressed or gene not amplified"}]}

package/CodeSystem-nkrs-iccc3code.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-iccc3code","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-iccc3code defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">Ia<a name=\"nkrs-iccc3code-Ia\"> </a></td><td>Lymphoid leukaemias</td></tr><tr><td style=\"white-space:nowrap\">Ib<a name=\"nkrs-iccc3code-Ib\"> </a></td><td>Acute myeloid leukemias</td></tr><tr><td style=\"white-space:nowrap\">Ic<a name=\"nkrs-iccc3code-Ic\"> </a></td><td>Chronic myeloproliferative diseases</td></tr><tr><td style=\"white-space:nowrap\">Id<a name=\"nkrs-iccc3code-Id\"> </a></td><td>Myelodysplastic syndrome and other myeloproliferative diseases</td></tr><tr><td style=\"white-space:nowrap\">Ie<a name=\"nkrs-iccc3code-Ie\"> </a></td><td>Unspecified and other specified leukemias</td></tr><tr><td style=\"white-space:nowrap\">IIa<a name=\"nkrs-iccc3code-IIa\"> </a></td><td>Hodgkin lymphomas</td></tr><tr><td style=\"white-space:nowrap\">IIb<a name=\"nkrs-iccc3code-IIb\"> </a></td><td>Non-Hodgkin lymphomas (except Burkitt lymphoma)</td></tr><tr><td style=\"white-space:nowrap\">IIc<a name=\"nkrs-iccc3code-IIc\"> </a></td><td>Burkitt lymphoma</td></tr><tr><td style=\"white-space:nowrap\">IId<a name=\"nkrs-iccc3code-IId\"> </a></td><td>Miscellaneous lymphoreticular neoplasms</td></tr><tr><td style=\"white-space:nowrap\">IIe<a name=\"nkrs-iccc3code-IIe\"> </a></td><td>Unspecified lymphomas</td></tr><tr><td style=\"white-space:nowrap\">IIIa<a name=\"nkrs-iccc3code-IIIa\"> </a></td><td>Ependymomas and choroid plexus tumor</td></tr><tr><td style=\"white-space:nowrap\">IIIb<a name=\"nkrs-iccc3code-IIIb\"> </a></td><td>Astrocytomas</td></tr><tr><td style=\"white-space:nowrap\">IIIc<a name=\"nkrs-iccc3code-IIIc\"> </a></td><td>Intracranial and intraspinal embryonal tumors</td></tr><tr><td style=\"white-space:nowrap\">IIId<a name=\"nkrs-iccc3code-IIId\"> </a></td><td>Other gliomas</td></tr><tr><td style=\"white-space:nowrap\">IIIe<a name=\"nkrs-iccc3code-IIIe\"> </a></td><td>Other specified intracranial and intraspinal neoplasms</td></tr><tr><td style=\"white-space:nowrap\">IIIf<a name=\"nkrs-iccc3code-IIIf\"> </a></td><td>Unspecified intracranial and intraspinal neoplasms</td></tr><tr><td style=\"white-space:nowrap\">IVa<a name=\"nkrs-iccc3code-IVa\"> </a></td><td>Neuroblastoma and ganglioneuroblastoma</td></tr><tr><td style=\"white-space:nowrap\">IVb<a name=\"nkrs-iccc3code-IVb\"> </a></td><td>Other peripheral nervous cell tumors</td></tr><tr><td style=\"white-space:nowrap\">V<a name=\"nkrs-iccc3code-V\"> </a></td><td>Retinoblastoma</td></tr><tr><td style=\"white-space:nowrap\">VIa<a name=\"nkrs-iccc3code-VIa\"> </a></td><td>Nephroblastoma and other nonepithelial renal tumors</td></tr><tr><td style=\"white-space:nowrap\">VIb<a name=\"nkrs-iccc3code-VIb\"> </a></td><td>Renal carcinomas</td></tr><tr><td style=\"white-space:nowrap\">VIc<a name=\"nkrs-iccc3code-VIc\"> </a></td><td>Unspecified malignant renal tumors</td></tr><tr><td style=\"white-space:nowrap\">VIIa<a name=\"nkrs-iccc3code-VIIa\"> </a></td><td>Hepatoblastoma</td></tr><tr><td style=\"white-space:nowrap\">VIIb<a name=\"nkrs-iccc3code-VIIb\"> </a></td><td>Hepatic carcinomas</td></tr><tr><td style=\"white-space:nowrap\">VIIc<a name=\"nkrs-iccc3code-VIIc\"> </a></td><td>Unspecified malignant hepatic tumors</td></tr><tr><td style=\"white-space:nowrap\">VIIIa<a name=\"nkrs-iccc3code-VIIIa\"> </a></td><td>Osteosarcomas</td></tr><tr><td style=\"white-space:nowrap\">VIIIb<a name=\"nkrs-iccc3code-VIIIb\"> </a></td><td>Chondrosarcomas</td></tr><tr><td style=\"white-space:nowrap\">VIIIc<a name=\"nkrs-iccc3code-VIIIc\"> </a></td><td>Ewing tumor and related sarcomas of bone</td></tr><tr><td style=\"white-space:nowrap\">VIIId<a name=\"nkrs-iccc3code-VIIId\"> </a></td><td>Other specified malignant bone tumors</td></tr><tr><td style=\"white-space:nowrap\">VIIIe<a name=\"nkrs-iccc3code-VIIIe\"> </a></td><td>Unspecified malignant bone tumors</td></tr><tr><td style=\"white-space:nowrap\">IXa<a name=\"nkrs-iccc3code-IXa\"> </a></td><td>Rhabdomyosarcomas</td></tr><tr><td style=\"white-space:nowrap\">IXb<a name=\"nkrs-iccc3code-IXb\"> </a></td><td>Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms</td></tr><tr><td style=\"white-space:nowrap\">IXc<a name=\"nkrs-iccc3code-IXc\"> </a></td><td>Kaposi sarcoma</td></tr><tr><td style=\"white-space:nowrap\">IXd<a name=\"nkrs-iccc3code-IXd\"> </a></td><td>Other specified soft tissue sarcomas</td></tr><tr><td style=\"white-space:nowrap\">IXe<a name=\"nkrs-iccc3code-IXe\"> </a></td><td>Unspecified soft tissue sarcomas</td></tr><tr><td style=\"white-space:nowrap\">Xa<a name=\"nkrs-iccc3code-Xa\"> </a></td><td>Intracranial and intraspinal germ cell tumors</td></tr><tr><td style=\"white-space:nowrap\">Xb<a name=\"nkrs-iccc3code-Xb\"> </a></td><td>Malignant extracranial and extragonadal germ cell tumors</td></tr><tr><td style=\"white-space:nowrap\">Xc<a name=\"nkrs-iccc3code-Xc\"> </a></td><td>Malignant gonadal germ cell tumors</td></tr><tr><td style=\"white-space:nowrap\">Xd<a name=\"nkrs-iccc3code-Xd\"> </a></td><td>Gonadal carcinomas</td></tr><tr><td style=\"white-space:nowrap\">Xe<a name=\"nkrs-iccc3code-Xe\"> </a></td><td>Other and unspecified malignant gonadal tumors</td></tr><tr><td style=\"white-space:nowrap\">XIa<a name=\"nkrs-iccc3code-XIa\"> </a></td><td>Adrenocortical carcinomas</td></tr><tr><td style=\"white-space:nowrap\">XIb<a name=\"nkrs-iccc3code-XIb\"> </a></td><td>Thyroid carcinomas</td></tr><tr><td style=\"white-space:nowrap\">XIc<a name=\"nkrs-iccc3code-XIc\"> </a></td><td>Nasopharyngeal carcinomas</td></tr><tr><td style=\"white-space:nowrap\">XId<a name=\"nkrs-iccc3code-XId\"> </a></td><td>Malignant melanomas</td></tr><tr><td style=\"white-space:nowrap\">XIe<a name=\"nkrs-iccc3code-XIe\"> </a></td><td>Skin carcinomas</td></tr><tr><td style=\"white-space:nowrap\">XIf<a name=\"nkrs-iccc3code-XIf\"> </a></td><td>Other and unspecified carcinomas</td></tr><tr><td style=\"white-space:nowrap\">XIIa<a name=\"nkrs-iccc3code-XIIa\"> </a></td><td>Other specified malignant tumors</td></tr><tr><td style=\"white-space:nowrap\">XIIb<a name=\"nkrs-iccc3code-XIIb\"> </a></td><td>Other unspecified malignant tumours</td></tr><tr><td style=\"white-space:nowrap\">140<a name=\"nkrs-iccc3code-140\"> </a></td><td>Langerhans cell histiocytosis</td></tr><tr><td style=\"white-space:nowrap\">150<a name=\"nkrs-iccc3code-150\"> </a></td><td>Neoplasms of uncertain behaviour or in situ</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-iccc3code","version":"0.9.0","name":"NkrsICCC3Code","title":"NKRS - ICCC-3 Code","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"This data item records detailed division of the diagnostic group according to the third revision \r\nof the 1996 International Classification of Childhood Cancer (ICCC-3). \r\n\r\n**ICCC-3 code (Variable number: 3.9.2)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-iccc3code","content":"complete","count":50,"concept":[{"code":"Ia","display":"Lymphoid leukaemias"},{"code":"Ib","display":"Acute myeloid leukemias"},{"code":"Ic","display":"Chronic myeloproliferative diseases"},{"code":"Id","display":"Myelodysplastic syndrome and other myeloproliferative diseases"},{"code":"Ie","display":"Unspecified and other specified leukemias"},{"code":"IIa","display":"Hodgkin lymphomas"},{"code":"IIb","display":"Non-Hodgkin lymphomas (except Burkitt lymphoma)"},{"code":"IIc","display":"Burkitt lymphoma"},{"code":"IId","display":"Miscellaneous lymphoreticular neoplasms"},{"code":"IIe","display":"Unspecified lymphomas"},{"code":"IIIa","display":"Ependymomas and choroid plexus tumor"},{"code":"IIIb","display":"Astrocytomas"},{"code":"IIIc","display":"Intracranial and intraspinal embryonal tumors"},{"code":"IIId","display":"Other gliomas"},{"code":"IIIe","display":"Other specified intracranial and intraspinal neoplasms"},{"code":"IIIf","display":"Unspecified intracranial and intraspinal neoplasms"},{"code":"IVa","display":"Neuroblastoma and ganglioneuroblastoma"},{"code":"IVb","display":"Other peripheral nervous cell tumors"},{"code":"V","display":"Retinoblastoma"},{"code":"VIa","display":"Nephroblastoma and other nonepithelial renal tumors"},{"code":"VIb","display":"Renal carcinomas"},{"code":"VIc","display":"Unspecified malignant renal tumors"},{"code":"VIIa","display":"Hepatoblastoma"},{"code":"VIIb","display":"Hepatic carcinomas"},{"code":"VIIc","display":"Unspecified malignant hepatic tumors"},{"code":"VIIIa","display":"Osteosarcomas"},{"code":"VIIIb","display":"Chondrosarcomas"},{"code":"VIIIc","display":"Ewing tumor and related sarcomas of bone"},{"code":"VIIId","display":"Other specified malignant bone tumors"},{"code":"VIIIe","display":"Unspecified malignant bone tumors"},{"code":"IXa","display":"Rhabdomyosarcomas"},{"code":"IXb","display":"Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms"},{"code":"IXc","display":"Kaposi sarcoma"},{"code":"IXd","display":"Other specified soft tissue sarcomas"},{"code":"IXe","display":"Unspecified soft tissue sarcomas"},{"code":"Xa","display":"Intracranial and intraspinal germ cell tumors"},{"code":"Xb","display":"Malignant extracranial and extragonadal germ cell tumors"},{"code":"Xc","display":"Malignant gonadal germ cell tumors"},{"code":"Xd","display":"Gonadal carcinomas"},{"code":"Xe","display":"Other and unspecified malignant gonadal tumors"},{"code":"XIa","display":"Adrenocortical carcinomas"},{"code":"XIb","display":"Thyroid carcinomas"},{"code":"XIc","display":"Nasopharyngeal carcinomas"},{"code":"XId","display":"Malignant melanomas"},{"code":"XIe","display":"Skin carcinomas"},{"code":"XIf","display":"Other and unspecified carcinomas"},{"code":"XIIa","display":"Other specified malignant tumors"},{"code":"XIIb","display":"Other unspecified malignant tumours"},{"code":"140","display":"Langerhans cell histiocytosis"},{"code":"150","display":"Neoplasms of uncertain behaviour or in situ"}]}

package/CodeSystem-nkrs-iccc3extendedcode.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-iccc3extendedcode","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-iccc3extendedcode defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">Ia.1<a name=\"nkrs-iccc3extendedcode-Ia.461\"> </a></td><td>Precursor cell leukaemias</td></tr><tr><td style=\"white-space:nowrap\">Ia.2<a name=\"nkrs-iccc3extendedcode-Ia.462\"> </a></td><td>Mature B-cell leukaemias</td></tr><tr><td style=\"white-space:nowrap\">Ia.3<a name=\"nkrs-iccc3extendedcode-Ia.463\"> </a></td><td>Mature T-cell and NK cell leukaemias</td></tr><tr><td style=\"white-space:nowrap\">Ia.4<a name=\"nkrs-iccc3extendedcode-Ia.464\"> </a></td><td>Lymphoid leukaemia, NOS</td></tr><tr><td style=\"white-space:nowrap\">IIb.1<a name=\"nkrs-iccc3extendedcode-IIb.461\"> </a></td><td>Precursor cell lymphomas</td></tr><tr><td style=\"white-space:nowrap\">IIb.2<a name=\"nkrs-iccc3extendedcode-IIb.462\"> </a></td><td>Mature B-cell lymphomas (except Burkitt lymphoma)</td></tr><tr><td style=\"white-space:nowrap\">IIb.3<a name=\"nkrs-iccc3extendedcode-IIb.463\"> </a></td><td>Mature T-cell and NK-cell lymphomas</td></tr><tr><td style=\"white-space:nowrap\">IIb.4<a name=\"nkrs-iccc3extendedcode-IIb.464\"> </a></td><td>Non-Hodgkin lymphomas, NOS</td></tr><tr><td style=\"white-space:nowrap\">IIIa.1<a name=\"nkrs-iccc3extendedcode-IIIa.461\"> </a></td><td>Ependymomas</td></tr><tr><td style=\"white-space:nowrap\">IIIa.2<a name=\"nkrs-iccc3extendedcode-IIIa.462\"> </a></td><td>Choroid plexus tumour</td></tr><tr><td style=\"white-space:nowrap\">IIIc.1<a name=\"nkrs-iccc3extendedcode-IIIc.461\"> </a></td><td>Medulloblastomas</td></tr><tr><td style=\"white-space:nowrap\">IIIc.2<a name=\"nkrs-iccc3extendedcode-IIIc.462\"> </a></td><td>PNET</td></tr><tr><td style=\"white-space:nowrap\">IIIc.3<a name=\"nkrs-iccc3extendedcode-IIIc.463\"> </a></td><td>Medulloepithelioma</td></tr><tr><td style=\"white-space:nowrap\">IIIc.4<a name=\"nkrs-iccc3extendedcode-IIIc.464\"> </a></td><td>Atypical teratoid/rhabdoid tumour</td></tr><tr><td style=\"white-space:nowrap\">IIId.1<a name=\"nkrs-iccc3extendedcode-IIId.461\"> </a></td><td>Oligodendrogliomas</td></tr><tr><td style=\"white-space:nowrap\">IIId.2<a name=\"nkrs-iccc3extendedcode-IIId.462\"> </a></td><td>Mixed and unspecified gliomas</td></tr><tr><td style=\"white-space:nowrap\">IIId.3<a name=\"nkrs-iccc3extendedcode-IIId.463\"> </a></td><td>Neuroepithelial glial tumours of uncertain origin</td></tr><tr><td style=\"white-space:nowrap\">IIIe.1<a name=\"nkrs-iccc3extendedcode-IIIe.461\"> </a></td><td>Pituitary adenomas and carcinomas</td></tr><tr><td style=\"white-space:nowrap\">IIIe.2<a name=\"nkrs-iccc3extendedcode-IIIe.462\"> </a></td><td>Tumours of the sellar region (craniopharyngiomas)</td></tr><tr><td style=\"white-space:nowrap\">IIIe.3<a name=\"nkrs-iccc3extendedcode-IIIe.463\"> </a></td><td>Pineal parenchymal tumours</td></tr><tr><td style=\"white-space:nowrap\">IIIe.4<a name=\"nkrs-iccc3extendedcode-IIIe.464\"> </a></td><td>Neuronal and mixed neuronal-glial tumours</td></tr><tr><td style=\"white-space:nowrap\">IIIe.5<a name=\"nkrs-iccc3extendedcode-IIIe.465\"> </a></td><td>Meningiomas</td></tr><tr><td style=\"white-space:nowrap\">VIa.1<a name=\"nkrs-iccc3extendedcode-VIa.461\"> </a></td><td>Nephroblastoma</td></tr><tr><td style=\"white-space:nowrap\">VIa.2<a name=\"nkrs-iccc3extendedcode-VIa.462\"> </a></td><td>Rhabdoid renal tumour</td></tr><tr><td style=\"white-space:nowrap\">VIa.3<a name=\"nkrs-iccc3extendedcode-VIa.463\"> </a></td><td>Kidney sarcomas</td></tr><tr><td style=\"white-space:nowrap\">VIa.4<a name=\"nkrs-iccc3extendedcode-VIa.464\"> </a></td><td>pPNET of kidney</td></tr><tr><td style=\"white-space:nowrap\">VIIIc.1<a name=\"nkrs-iccc3extendedcode-VIIIc.461\"> </a></td><td>Ewing tumour and Askin tumour of bone</td></tr><tr><td style=\"white-space:nowrap\">VIIIc.2<a name=\"nkrs-iccc3extendedcode-VIIIc.462\"> </a></td><td>pPNET of bone</td></tr><tr><td style=\"white-space:nowrap\">VIIId.1<a name=\"nkrs-iccc3extendedcode-VIIId.461\"> </a></td><td>Malignant fibrous neoplasms of bone</td></tr><tr><td style=\"white-space:nowrap\">VIIId.2<a name=\"nkrs-iccc3extendedcode-VIIId.462\"> </a></td><td>Malignant chordomas</td></tr><tr><td style=\"white-space:nowrap\">VIIId.3<a name=\"nkrs-iccc3extendedcode-VIIId.463\"> </a></td><td>Odontogenic malignant tumours</td></tr><tr><td style=\"white-space:nowrap\">VIIId.4<a name=\"nkrs-iccc3extendedcode-VIIId.464\"> </a></td><td>Miscellaneous malignant bone tumours</td></tr><tr><td style=\"white-space:nowrap\">IXb.1<a name=\"nkrs-iccc3extendedcode-IXb.461\"> </a></td><td>Fibroblastic and myofibroblastic tumours</td></tr><tr><td style=\"white-space:nowrap\">IXb.2<a name=\"nkrs-iccc3extendedcode-IXb.462\"> </a></td><td>Nerve sheath tumours</td></tr><tr><td style=\"white-space:nowrap\">IXb.3<a name=\"nkrs-iccc3extendedcode-IXb.463\"> </a></td><td>Other fibromatous neoplasms</td></tr><tr><td style=\"white-space:nowrap\">IXd.1<a name=\"nkrs-iccc3extendedcode-IXd.461\"> </a></td><td>Ewing tumour and Askin tumour of soft tissue</td></tr><tr><td style=\"white-space:nowrap\">IXd.2<a name=\"nkrs-iccc3extendedcode-IXd.462\"> </a></td><td>pPNET of soft tissue</td></tr><tr><td style=\"white-space:nowrap\">IXd.3<a name=\"nkrs-iccc3extendedcode-IXd.463\"> </a></td><td>Extrarenal rhabdoid tumour</td></tr><tr><td style=\"white-space:nowrap\">IXd.4<a name=\"nkrs-iccc3extendedcode-IXd.464\"> </a></td><td>Liposarcomas</td></tr><tr><td style=\"white-space:nowrap\">IXd.5<a name=\"nkrs-iccc3extendedcode-IXd.465\"> </a></td><td>Fibrohistiocytic tumours</td></tr><tr><td style=\"white-space:nowrap\">IXd.6<a name=\"nkrs-iccc3extendedcode-IXd.466\"> </a></td><td>Leiomyosarcomas</td></tr><tr><td style=\"white-space:nowrap\">IXd.7<a name=\"nkrs-iccc3extendedcode-IXd.467\"> </a></td><td>Synovial sarcomas</td></tr><tr><td style=\"white-space:nowrap\">IXd.8<a name=\"nkrs-iccc3extendedcode-IXd.468\"> </a></td><td>Blood vessel tumours</td></tr><tr><td style=\"white-space:nowrap\">IXd.9<a name=\"nkrs-iccc3extendedcode-IXd.469\"> </a></td><td>Osseous and chondromatous neoplasms of soft tissue</td></tr><tr><td style=\"white-space:nowrap\">IXd.10<a name=\"nkrs-iccc3extendedcode-IXd.4610\"> </a></td><td>Alveolar soft parts sarcoma</td></tr><tr><td style=\"white-space:nowrap\">IXd.11<a name=\"nkrs-iccc3extendedcode-IXd.4611\"> </a></td><td>Miscellaneous soft tissue sarcomas</td></tr><tr><td style=\"white-space:nowrap\">Xa.1<a name=\"nkrs-iccc3extendedcode-Xa.461\"> </a></td><td>Intracranial and intraspinal germinomas</td></tr><tr><td style=\"white-space:nowrap\">Xa.2<a name=\"nkrs-iccc3extendedcode-Xa.462\"> </a></td><td>Intracranial and intraspinal teratomas</td></tr><tr><td style=\"white-space:nowrap\">Xa.3<a name=\"nkrs-iccc3extendedcode-Xa.463\"> </a></td><td>Intracranial and intraspinal embryonal carcinomas</td></tr><tr><td style=\"white-space:nowrap\">Xa.4<a name=\"nkrs-iccc3extendedcode-Xa.464\"> </a></td><td>Intracranial and intraspinal yolk sac tumour</td></tr><tr><td style=\"white-space:nowrap\">Xa.5<a name=\"nkrs-iccc3extendedcode-Xa.465\"> </a></td><td>Intracranial and intraspinal choriocarcinoma</td></tr><tr><td style=\"white-space:nowrap\">Xa.6<a name=\"nkrs-iccc3extendedcode-Xa.466\"> </a></td><td>Intracranial and intraspinal tumours of mixed forms</td></tr><tr><td style=\"white-space:nowrap\">Xb.1<a name=\"nkrs-iccc3extendedcode-Xb.461\"> </a></td><td>Malignant germinomas of extracranial and extragonadal sites</td></tr><tr><td style=\"white-space:nowrap\">Xb.2<a name=\"nkrs-iccc3extendedcode-Xb.462\"> </a></td><td>Malignant teratomas of extracranial and extragonadal sites</td></tr><tr><td style=\"white-space:nowrap\">Xb.3<a name=\"nkrs-iccc3extendedcode-Xb.463\"> </a></td><td>Embryonal carcinomas of extracranial and extragonadal sites</td></tr><tr><td style=\"white-space:nowrap\">Xb.4<a name=\"nkrs-iccc3extendedcode-Xb.464\"> </a></td><td>Yolk sac tumour of extracranial and extragonadal sites</td></tr><tr><td style=\"white-space:nowrap\">Xb.5<a name=\"nkrs-iccc3extendedcode-Xb.465\"> </a></td><td>Choriocarcinomas of extracranial and extragonadal sites</td></tr><tr><td style=\"white-space:nowrap\">Xb.6<a name=\"nkrs-iccc3extendedcode-Xb.466\"> </a></td><td>Other and unspecified malignant mixed germ cell tumors of extracranial and extragonadal sites</td></tr><tr><td style=\"white-space:nowrap\">Xc.1<a name=\"nkrs-iccc3extendedcode-Xc.461\"> </a></td><td>Malignant gonadal germinomas</td></tr><tr><td style=\"white-space:nowrap\">Xc.2<a name=\"nkrs-iccc3extendedcode-Xc.462\"> </a></td><td>Malignant gonadal teratomas</td></tr><tr><td style=\"white-space:nowrap\">Xc.3<a name=\"nkrs-iccc3extendedcode-Xc.463\"> </a></td><td>Gonadal embryonal carcinomas</td></tr><tr><td style=\"white-space:nowrap\">Xc.4<a name=\"nkrs-iccc3extendedcode-Xc.464\"> </a></td><td>Gonadal yolk sac tumour</td></tr><tr><td style=\"white-space:nowrap\">Xc.5<a name=\"nkrs-iccc3extendedcode-Xc.465\"> </a></td><td>Gonadal choriocarcinoma</td></tr><tr><td style=\"white-space:nowrap\">Xc.6<a name=\"nkrs-iccc3extendedcode-Xc.466\"> </a></td><td>Malignant gonadal tumours of mixed forms</td></tr><tr><td style=\"white-space:nowrap\">Xc.7<a name=\"nkrs-iccc3extendedcode-Xc.467\"> </a></td><td>Malignant gonadal gonadoblastoma</td></tr><tr><td style=\"white-space:nowrap\">XIf.1<a name=\"nkrs-iccc3extendedcode-XIf.461\"> </a></td><td>Carcinomas of salivary glands</td></tr><tr><td style=\"white-space:nowrap\">XIf.2<a name=\"nkrs-iccc3extendedcode-XIf.462\"> </a></td><td>Carcinomas of colon and rectum</td></tr><tr><td style=\"white-space:nowrap\">XIf.3<a name=\"nkrs-iccc3extendedcode-XIf.463\"> </a></td><td>Carcinomas of appendix</td></tr><tr><td style=\"white-space:nowrap\">XIf.4<a name=\"nkrs-iccc3extendedcode-XIf.464\"> </a></td><td>Carcinomas of lung</td></tr><tr><td style=\"white-space:nowrap\">XIf.5<a name=\"nkrs-iccc3extendedcode-XIf.465\"> </a></td><td>Carcinomas of thymus</td></tr><tr><td style=\"white-space:nowrap\">XIf.6<a name=\"nkrs-iccc3extendedcode-XIf.466\"> </a></td><td>Carcinomas of breast</td></tr><tr><td style=\"white-space:nowrap\">XIf.7<a name=\"nkrs-iccc3extendedcode-XIf.467\"> </a></td><td>Carcinomas of cervix uteri</td></tr><tr><td style=\"white-space:nowrap\">XIf.8<a name=\"nkrs-iccc3extendedcode-XIf.468\"> </a></td><td>Carcinomas of bladder</td></tr><tr><td style=\"white-space:nowrap\">XIf.9<a name=\"nkrs-iccc3extendedcode-XIf.469\"> </a></td><td>Carcinomas of eye</td></tr><tr><td style=\"white-space:nowrap\">XIf.10<a name=\"nkrs-iccc3extendedcode-XIf.4610\"> </a></td><td>Carcinomas of other specified sites</td></tr><tr><td style=\"white-space:nowrap\">XIf.11<a name=\"nkrs-iccc3extendedcode-XIf.4611\"> </a></td><td>Carcinomas of unspecified site</td></tr><tr><td style=\"white-space:nowrap\">XIIa.1<a name=\"nkrs-iccc3extendedcode-XIIa.461\"> </a></td><td>Gastrointestinal stromal tumour</td></tr><tr><td style=\"white-space:nowrap\">XIIa.2<a name=\"nkrs-iccc3extendedcode-XIIa.462\"> </a></td><td>Pancreatoblastoma</td></tr><tr><td style=\"white-space:nowrap\">XIIa.3<a name=\"nkrs-iccc3extendedcode-XIIa.463\"> </a></td><td>Pulmonary blastoma and pleuropulmonary blastoma</td></tr><tr><td style=\"white-space:nowrap\">XIIa.4<a name=\"nkrs-iccc3extendedcode-XIIa.464\"> </a></td><td>Other complex mixed and stromal neoplasms</td></tr><tr><td style=\"white-space:nowrap\">XIIa.5<a name=\"nkrs-iccc3extendedcode-XIIa.465\"> </a></td><td>Mesothelioma</td></tr><tr><td style=\"white-space:nowrap\">XIIa.6<a name=\"nkrs-iccc3extendedcode-XIIa.466\"> </a></td><td>Other specified malignant tumours</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-iccc3extendedcode","version":"0.9.0","name":"NkrsICCC3ExtendedCode","title":"NKRS - ICCC-3 Extended Code","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"This data item records detailed division of the diagnostic group according to the third revision \r\nof the 1996 International Classification of Childhood Cancer (ICCC-3). \r\n\r\n**ICCC-3 code (Variable number: 3.9.3)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-iccc3extendedcode","content":"complete","count":82,"concept":[{"code":"Ia.1","display":"Precursor cell leukaemias"},{"code":"Ia.2","display":"Mature B-cell leukaemias"},{"code":"Ia.3","display":"Mature T-cell and NK cell leukaemias"},{"code":"Ia.4","display":"Lymphoid leukaemia, NOS"},{"code":"IIb.1","display":"Precursor cell lymphomas"},{"code":"IIb.2","display":"Mature B-cell lymphomas (except Burkitt lymphoma)"},{"code":"IIb.3","display":"Mature T-cell and NK-cell lymphomas"},{"code":"IIb.4","display":"Non-Hodgkin lymphomas, NOS"},{"code":"IIIa.1","display":"Ependymomas"},{"code":"IIIa.2","display":"Choroid plexus tumour"},{"code":"IIIc.1","display":"Medulloblastomas"},{"code":"IIIc.2","display":"PNET"},{"code":"IIIc.3","display":"Medulloepithelioma"},{"code":"IIIc.4","display":"Atypical teratoid/rhabdoid tumour"},{"code":"IIId.1","display":"Oligodendrogliomas"},{"code":"IIId.2","display":"Mixed and unspecified gliomas"},{"code":"IIId.3","display":"Neuroepithelial glial tumours of uncertain origin"},{"code":"IIIe.1","display":"Pituitary adenomas and carcinomas"},{"code":"IIIe.2","display":"Tumours of the sellar region (craniopharyngiomas)"},{"code":"IIIe.3","display":"Pineal parenchymal tumours"},{"code":"IIIe.4","display":"Neuronal and mixed neuronal-glial tumours"},{"code":"IIIe.5","display":"Meningiomas"},{"code":"VIa.1","display":"Nephroblastoma"},{"code":"VIa.2","display":"Rhabdoid renal tumour"},{"code":"VIa.3","display":"Kidney sarcomas"},{"code":"VIa.4","display":"pPNET of kidney"},{"code":"VIIIc.1","display":"Ewing tumour and Askin tumour of bone"},{"code":"VIIIc.2","display":"pPNET of bone"},{"code":"VIIId.1","display":"Malignant fibrous neoplasms of bone"},{"code":"VIIId.2","display":"Malignant chordomas"},{"code":"VIIId.3","display":"Odontogenic malignant tumours"},{"code":"VIIId.4","display":"Miscellaneous malignant bone tumours"},{"code":"IXb.1","display":"Fibroblastic and myofibroblastic tumours"},{"code":"IXb.2","display":"Nerve sheath tumours"},{"code":"IXb.3","display":"Other fibromatous neoplasms"},{"code":"IXd.1","display":"Ewing tumour and Askin tumour of soft tissue"},{"code":"IXd.2","display":"pPNET of soft tissue"},{"code":"IXd.3","display":"Extrarenal rhabdoid tumour"},{"code":"IXd.4","display":"Liposarcomas"},{"code":"IXd.5","display":"Fibrohistiocytic tumours"},{"code":"IXd.6","display":"Leiomyosarcomas"},{"code":"IXd.7","display":"Synovial sarcomas"},{"code":"IXd.8","display":"Blood vessel tumours"},{"code":"IXd.9","display":"Osseous and chondromatous neoplasms of soft tissue"},{"code":"IXd.10","display":"Alveolar soft parts sarcoma"},{"code":"IXd.11","display":"Miscellaneous soft tissue sarcomas"},{"code":"Xa.1","display":"Intracranial and intraspinal germinomas"},{"code":"Xa.2","display":"Intracranial and intraspinal teratomas"},{"code":"Xa.3","display":"Intracranial and intraspinal embryonal carcinomas"},{"code":"Xa.4","display":"Intracranial and intraspinal yolk sac tumour"},{"code":"Xa.5","display":"Intracranial and intraspinal choriocarcinoma"},{"code":"Xa.6","display":"Intracranial and intraspinal tumours of mixed forms"},{"code":"Xb.1","display":"Malignant germinomas of extracranial and extragonadal sites"},{"code":"Xb.2","display":"Malignant teratomas of extracranial and extragonadal sites"},{"code":"Xb.3","display":"Embryonal carcinomas of extracranial and extragonadal sites"},{"code":"Xb.4","display":"Yolk sac tumour of extracranial and extragonadal sites"},{"code":"Xb.5","display":"Choriocarcinomas of extracranial and extragonadal sites"},{"code":"Xb.6","display":"Other and unspecified malignant mixed germ cell tumors of extracranial and extragonadal sites"},{"code":"Xc.1","display":"Malignant gonadal germinomas"},{"code":"Xc.2","display":"Malignant gonadal teratomas"},{"code":"Xc.3","display":"Gonadal embryonal carcinomas"},{"code":"Xc.4","display":"Gonadal yolk sac tumour"},{"code":"Xc.5","display":"Gonadal choriocarcinoma"},{"code":"Xc.6","display":"Malignant gonadal tumours of mixed forms"},{"code":"Xc.7","display":"Malignant gonadal gonadoblastoma"},{"code":"XIf.1","display":"Carcinomas of salivary glands"},{"code":"XIf.2","display":"Carcinomas of colon and rectum"},{"code":"XIf.3","display":"Carcinomas of appendix"},{"code":"XIf.4","display":"Carcinomas of lung"},{"code":"XIf.5","display":"Carcinomas of thymus"},{"code":"XIf.6","display":"Carcinomas of breast"},{"code":"XIf.7","display":"Carcinomas of cervix uteri"},{"code":"XIf.8","display":"Carcinomas of bladder"},{"code":"XIf.9","display":"Carcinomas of eye"},{"code":"XIf.10","display":"Carcinomas of other specified sites"},{"code":"XIf.11","display":"Carcinomas of unspecified site"},{"code":"XIIa.1","display":"Gastrointestinal stromal tumour"},{"code":"XIIa.2","display":"Pancreatoblastoma"},{"code":"XIIa.3","display":"Pulmonary blastoma and pleuropulmonary blastoma"},{"code":"XIIa.4","display":"Other complex mixed and stromal neoplasms"},{"code":"XIIa.5","display":"Mesothelioma"},{"code":"XIIa.6","display":"Other specified malignant tumours"}]}

package/CodeSystem-nkrs-iccc3maingroup.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-iccc3maingroup","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-iccc3maingroup defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">I<a name=\"nkrs-iccc3maingroup-I\"> </a></td><td>Leukaemias, myeloproliferative diseases, and myelodysplastic diseases</td></tr><tr><td style=\"white-space:nowrap\">II<a name=\"nkrs-iccc3maingroup-II\"> </a></td><td>Lymphomas and reticuloendothelial neoplasms</td></tr><tr><td style=\"white-space:nowrap\">III<a name=\"nkrs-iccc3maingroup-III\"> </a></td><td>CNS and miscellaneous intracranial and intraspinal neoplasms</td></tr><tr><td style=\"white-space:nowrap\">IV<a name=\"nkrs-iccc3maingroup-IV\"> </a></td><td>Neuroblastoma and other peripheral nervous cell tumours</td></tr><tr><td style=\"white-space:nowrap\">V<a name=\"nkrs-iccc3maingroup-V\"> </a></td><td>Retinoblastoma</td></tr><tr><td style=\"white-space:nowrap\">VI<a name=\"nkrs-iccc3maingroup-VI\"> </a></td><td>Renal tumours</td></tr><tr><td style=\"white-space:nowrap\">VII<a name=\"nkrs-iccc3maingroup-VII\"> </a></td><td>Hepatic tumours</td></tr><tr><td style=\"white-space:nowrap\">VIII<a name=\"nkrs-iccc3maingroup-VIII\"> </a></td><td>Malignant bone tumours</td></tr><tr><td style=\"white-space:nowrap\">IX<a name=\"nkrs-iccc3maingroup-IX\"> </a></td><td>Soft tissue and other extraosseous sarcomas</td></tr><tr><td style=\"white-space:nowrap\">X<a name=\"nkrs-iccc3maingroup-X\"> </a></td><td>Germ cell tumours, trophoblastic tumours, and neoplasms of gonads</td></tr><tr><td style=\"white-space:nowrap\">XI<a name=\"nkrs-iccc3maingroup-XI\"> </a></td><td>Other malignant epithelial neoplasms and malignant melanomas</td></tr><tr><td style=\"white-space:nowrap\">XII<a name=\"nkrs-iccc3maingroup-XII\"> </a></td><td>Other and unspecified malignant neoplasms</td></tr><tr><td style=\"white-space:nowrap\">14<a name=\"nkrs-iccc3maingroup-14\"> </a></td><td>Langerhans cell histiocytosis</td></tr><tr><td style=\"white-space:nowrap\">15<a name=\"nkrs-iccc3maingroup-15\"> </a></td><td>Neoplasms of uncertain behaviour or in situ</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-iccc3maingroup","version":"0.9.0","name":"NkrsICCC3MainGroup","title":"NKRS - ICCC-3 Main Group","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"This data item records the main diagnostic group according to the third revision (2005) \r\nof the 1996 International Classification of Childhood Cancer (ICCC-3). \r\n\r\n**ICCC-3 main group (Variable number: 3.9.1)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-iccc3maingroup","content":"complete","count":14,"concept":[{"code":"I","display":"Leukaemias, myeloproliferative diseases, and myelodysplastic diseases"},{"code":"II","display":"Lymphomas and reticuloendothelial neoplasms"},{"code":"III","display":"CNS and miscellaneous intracranial and intraspinal neoplasms"},{"code":"IV","display":"Neuroblastoma and other peripheral nervous cell tumours"},{"code":"V","display":"Retinoblastoma"},{"code":"VI","display":"Renal tumours"},{"code":"VII","display":"Hepatic tumours"},{"code":"VIII","display":"Malignant bone tumours"},{"code":"IX","display":"Soft tissue and other extraosseous sarcomas"},{"code":"X","display":"Germ cell tumours, trophoblastic tumours, and neoplasms of gonads"},{"code":"XI","display":"Other malignant epithelial neoplasms and malignant melanomas"},{"code":"XII","display":"Other and unspecified malignant neoplasms"},{"code":"14","display":"Langerhans cell histiocytosis"},{"code":"15","display":"Neoplasms of uncertain behaviour or in situ"}]}

package/CodeSystem-nkrs-icdo3behaviour.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-icdo3behaviour","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-icdo3behaviour defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">0<a name=\"nkrs-icdo3behaviour-0\"> </a></td><td>Benign</td><td>Benign tumours do not metastasize or locally invade tissues.</td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-icdo3behaviour-1\"> </a></td><td>Borderline</td><td>Uncertain whether benign or malignant. Low, borderline, or uncertain malignant potential.</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-icdo3behaviour-2\"> </a></td><td>In situ</td><td>Carcinoma in situ; intraepithelial; non-infiltrating; non-invasive.</td></tr><tr><td style=\"white-space:nowrap\">3<a name=\"nkrs-icdo3behaviour-3\"> </a></td><td>Malignant</td><td>Invasive behaviour.</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-icdo3behaviour","version":"0.9.0","name":"NkrsIcdO3Behaviour","title":"NKRS - ICD-O-3 Behaviour","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"This data item records the behaviour of the neoplasm at time of diagnosis according to ICD-O. \r\n\r\n**ICD-O Behaviour (Variable number: 3.6.1)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-icdo3behaviour","content":"complete","count":4,"concept":[{"code":"0","display":"Benign","definition":"Benign tumours do not metastasize or locally invade tissues."},{"code":"1","display":"Borderline","definition":"Uncertain whether benign or malignant. Low, borderline, or uncertain malignant potential."},{"code":"2","display":"In situ","definition":"Carcinoma in situ; intraepithelial; non-infiltrating; non-invasive."},{"code":"3","display":"Malignant","definition":"Invasive behaviour."}]}

package/CodeSystem-nkrs-icdo3histologicalgrade.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-icdo3histologicalgrade","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-icdo3histologicalgrade defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-icdo3histologicalgrade-1\"> </a></td><td>Grade I</td><td>Well differentiated; Differentiated, NOS; Low grade</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-icdo3histologicalgrade-2\"> </a></td><td>Grade II</td><td>Moderately (well) differentiated; Intermediate differentiation.</td></tr><tr><td style=\"white-space:nowrap\">3<a name=\"nkrs-icdo3histologicalgrade-3\"> </a></td><td>Grade III</td><td>Poorly differentiated; Dedifferentiated; High grade.</td></tr><tr><td style=\"white-space:nowrap\">4<a name=\"nkrs-icdo3histologicalgrade-4\"> </a></td><td>Grade IV</td><td>Undifferentiated; Anaplastic.</td></tr><tr><td style=\"white-space:nowrap\">5<a name=\"nkrs-icdo3histologicalgrade-5\"> </a></td><td>T-cell</td><td>T-cell; T-precursor.</td></tr><tr><td style=\"white-space:nowrap\">6<a name=\"nkrs-icdo3histologicalgrade-6\"> </a></td><td>B-cell</td><td>B-cell; Pre-B; B-precursor.</td></tr><tr><td style=\"white-space:nowrap\">7<a name=\"nkrs-icdo3histologicalgrade-7\"> </a></td><td>Null cell</td><td>Null cell; Non-T-non-B.</td></tr><tr><td style=\"white-space:nowrap\">8<a name=\"nkrs-icdo3histologicalgrade-8\"> </a></td><td>NK cell</td><td>NK cell; Natural killer cell.</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-icdo3histologicalgrade","version":"0.9.0","name":"NkrsIcdO3HistologicalGrade","title":"NKRS - ICD-O-3 Histological Grade","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The data item describes the neoplasm’s resemblance to normal (parent) tissue according to ICD-O. \r\n\r\n**ICD-O Histological Grade (Variable number: 3.7)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-icdo3histologicalgrade","content":"complete","count":8,"concept":[{"code":"1","display":"Grade I","definition":"Well differentiated; Differentiated, NOS; Low grade"},{"code":"2","display":"Grade II","definition":"Moderately (well) differentiated; Intermediate differentiation."},{"code":"3","display":"Grade III","definition":"Poorly differentiated; Dedifferentiated; High grade."},{"code":"4","display":"Grade IV","definition":"Undifferentiated; Anaplastic."},{"code":"5","display":"T-cell","definition":"T-cell; T-precursor."},{"code":"6","display":"B-cell","definition":"B-cell; Pre-B; B-precursor."},{"code":"7","display":"Null cell","definition":"Null cell; Non-T-non-B."},{"code":"8","display":"NK cell","definition":"NK cell; Natural killer cell."}]}

package/CodeSystem-nkrs-icdo3laterality.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-icdo3laterality","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-icdo3laterality defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-icdo3laterality-1\"> </a></td><td>Right</td><td/></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-icdo3laterality-2\"> </a></td><td>Left</td><td/></tr><tr><td style=\"white-space:nowrap\">3<a name=\"nkrs-icdo3laterality-3\"> </a></td><td>Unilateral, NOS</td><td>Unilateral, but unknown whether right or left.</td></tr><tr><td style=\"white-space:nowrap\">4<a name=\"nkrs-icdo3laterality-4\"> </a></td><td>Bilateral</td><td>Origin of primary tumour is on both sides of a paired organ (when tumours of the same morphology are diagnosed simultaneously in both sides of a paired organ). Bilateral cancers are very rare, e.g. bilateral retinoblastoma, bilateral Wilms tumour of the kidney, or both ovaries involved simultaneously.</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-icdo3laterality","version":"0.9.0","name":"NkrsIcdO3Laterality","title":"NKRS - ICD-O-3 Laterality","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"Laterality describes the side of a paired organ or side of the body on which the reportable cancer originated. \r\n\r\n**Laterality (Variable number: 3.8)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-icdo3laterality","content":"complete","count":4,"concept":[{"code":"1","display":"Right"},{"code":"2","display":"Left"},{"code":"3","display":"Unilateral, NOS","definition":"Unilateral, but unknown whether right or left."},{"code":"4","display":"Bilateral","definition":"Origin of primary tumour is on both sides of a paired organ (when tumours of the same morphology are diagnosed simultaneously in both sides of a paired organ). Bilateral cancers are very rare, e.g. bilateral retinoblastoma, bilateral Wilms tumour of the kidney, or both ovaries involved simultaneously."}]}

package/CodeSystem-nkrs-inrgssstaging.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-inrgssstaging","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-inrgssstaging defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">L1<a name=\"nkrs-inrgssstaging-L1\"> </a></td><td>Stage L1</td><td>Localized tumour not involving vital structures as defined by the list of image-defined risk factors and confined to one body compartment.</td></tr><tr><td style=\"white-space:nowrap\">L2<a name=\"nkrs-inrgssstaging-L2\"> </a></td><td>Stage L2</td><td>Locoregional tumor with presence of one or more image-defined risk factors.</td></tr><tr><td style=\"white-space:nowrap\">M<a name=\"nkrs-inrgssstaging-M\"> </a></td><td>Stage M</td><td>Distant metastatic disease (except stage MS).</td></tr><tr><td style=\"white-space:nowrap\">MS<a name=\"nkrs-inrgssstaging-MS\"> </a></td><td>Stage MS</td><td>Metastatic disease in children younger than 18 months with metastases confined to skin, liver, and/or bone marrow.</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-inrgssstaging","version":"0.9.0","name":"NkrsINRGSSStaging","title":"NKRS - INRGSS Staging","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"This data item records the paediatric stage classification of the \r\nInternational Neuroblastoma Risk Group Staging System (INRGSS). \r\n\r\n**INRGSS staging (Variable number: 4.22)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-inrgssstaging","content":"complete","count":4,"concept":[{"code":"L1","display":"Stage L1","definition":"Localized tumour not involving vital structures as defined by the list of image-defined risk factors and confined to one body compartment."},{"code":"L2","display":"Stage L2","definition":"Locoregional tumor with presence of one or more image-defined risk factors."},{"code":"M","display":"Stage M","definition":"Distant metastatic disease (except stage MS)."},{"code":"MS","display":"Stage MS","definition":"Metastatic disease in children younger than 18 months with metastases confined to skin, liver, and/or bone marrow."}]}

package/CodeSystem-nkrs-irssstaging.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-irssstaging","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-irssstaging defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">0<a name=\"nkrs-irssstaging-0\"> </a></td><td>Stage 0</td><td>Patients treated conservatively. The tumour is confined to the globe. Enucleation has not been performed.</td></tr><tr><td style=\"white-space:nowrap\">pI<a name=\"nkrs-irssstaging-pI\"> </a></td><td>pStage I</td><td>Eye enucleated, completely resected histologically</td></tr><tr><td style=\"white-space:nowrap\">pII<a name=\"nkrs-irssstaging-pII\"> </a></td><td>pStage II</td><td>Eye enucleated, microscopic residual tumour</td></tr><tr><td style=\"white-space:nowrap\">pIIIa<a name=\"nkrs-irssstaging-pIIIa\"> </a></td><td>pStage IIIa</td><td>Regional extension: overt orbital disease</td></tr><tr><td style=\"white-space:nowrap\">pIIIb<a name=\"nkrs-irssstaging-pIIIb\"> </a></td><td>pStage IIIb</td><td>Regional extension: preauricular or cervical lymph node extension</td></tr><tr><td style=\"white-space:nowrap\">cIVa.1<a name=\"nkrs-irssstaging-cIVa.461\"> </a></td><td>cStage IVa.1</td><td>Haematogenous metastasis (without CNS involvement): single lesion</td></tr><tr><td style=\"white-space:nowrap\">cIVa.2<a name=\"nkrs-irssstaging-cIVa.462\"> </a></td><td>cStage IVa.2</td><td>Haematogenous metastasis (without CNS involvement): multiple lesions</td></tr><tr><td style=\"white-space:nowrap\">cIVb.1<a name=\"nkrs-irssstaging-cIVb.461\"> </a></td><td>cStage IVb.1</td><td>CNS extension (with or without any other site of regional or metastatic disease: prechiasmatic lesion</td></tr><tr><td style=\"white-space:nowrap\">cIVb.2<a name=\"nkrs-irssstaging-cIVb.462\"> </a></td><td>cStage IVb.2</td><td>CNS extension (with or without any other site of regional or metastatic disease: CNS mass</td></tr><tr><td style=\"white-space:nowrap\">cIVb.3<a name=\"nkrs-irssstaging-cIVb.463\"> </a></td><td>cStage IVb.3</td><td>CNS extension (with or without any other site of regional or metastatic disease: leptomeningeal and cerebrospinal fluid disease</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-irssstaging","version":"0.9.0","name":"NkrsIRSSStaging","title":"NKRS - IRSS Staging","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The paediatric International Retinoblastoma Staging System is based on extent \r\nof disease and the presence of overt extra-ocular extension after enucleation. \r\n\r\n**IRSS staging (Variable number: 4.23)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-irssstaging","content":"complete","count":10,"concept":[{"code":"0","display":"Stage 0","definition":"Patients treated conservatively. The tumour is confined to the globe. Enucleation has not been performed."},{"code":"pI","display":"pStage I","definition":"Eye enucleated, completely resected histologically"},{"code":"pII","display":"pStage II","definition":"Eye enucleated, microscopic residual tumour"},{"code":"pIIIa","display":"pStage IIIa","definition":"Regional extension: overt orbital disease"},{"code":"pIIIb","display":"pStage IIIb","definition":"Regional extension: preauricular or cervical lymph node extension"},{"code":"cIVa.1","display":"cStage IVa.1","definition":"Haematogenous metastasis (without CNS involvement): single lesion"},{"code":"cIVa.2","display":"cStage IVa.2","definition":"Haematogenous metastasis (without CNS involvement): multiple lesions"},{"code":"cIVb.1","display":"cStage IVb.1","definition":"CNS extension (with or without any other site of regional or metastatic disease: prechiasmatic lesion"},{"code":"cIVb.2","display":"cStage IVb.2","definition":"CNS extension (with or without any other site of regional or metastatic disease: CNS mass"},{"code":"cIVb.3","display":"cStage IVb.3","definition":"CNS extension (with or without any other site of regional or metastatic disease: leptomeningeal and cerebrospinal fluid disease"}]}

package/CodeSystem-nkrs-issstaging.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-issstaging","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-issstaging defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">I<a name=\"nkrs-issstaging-I\"> </a></td><td>Stage I</td><td>Serum β2-microglobulin level &lt; 3.5 mg/L and serum albumin level &gt; 3.5 g/dL.</td></tr><tr><td style=\"white-space:nowrap\">II<a name=\"nkrs-issstaging-II\"> </a></td><td>Stage II</td><td>(Not ISS stage I or III).</td></tr><tr><td style=\"white-space:nowrap\">III<a name=\"nkrs-issstaging-III\"> </a></td><td>Stage III</td><td>Serum β2-microglobulin level ≥ 5.5 mg/L.</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-issstaging","version":"0.9.0","name":"NkrsISSStaging","title":"NKRS - ISS Staging","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The data item records the International Staging System (ISS) for multiple myeloma. \r\n\r\n**ISS staging (Variable number: 4.29)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-issstaging","content":"complete","count":3,"concept":[{"code":"I","display":"Stage I","definition":"Serum β2-microglobulin level < 3.5 mg/L and serum albumin level > 3.5 g/dL."},{"code":"II","display":"Stage II","definition":"(Not ISS stage I or III)."},{"code":"III","display":"Stage III","definition":"Serum β2-microglobulin level ≥ 5.5 mg/L."}]}

package/CodeSystem-nkrs-ldh.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-ldh","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-ldh defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">0<a name=\"nkrs-ldh-0\"> </a></td><td>LDH0</td><td>Within reference range</td></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-ldh-1\"> </a></td><td>LDH1</td><td>&gt; upper limit of reference range if upper limit &lt; 1.5 x N^#</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-ldh-2\"> </a></td><td>LDH2</td><td>1.5 – 10 x N^#</td></tr><tr><td style=\"white-space:nowrap\">3<a name=\"nkrs-ldh-3\"> </a></td><td>LDH3</td><td>&gt; 10 x N^#</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-ldh","version":"0.9.0","name":"NkrsLDH","title":"NKRS - LDH","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The data item records the levels of serum tumour marker lactate dehydrogenase (LDH). \r\n\r\n**LDH (Variable number: 5.5.3)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-ldh","content":"complete","count":4,"concept":[{"code":"0","display":"LDH0","definition":"Within reference range"},{"code":"1","display":"LDH1","definition":"> upper limit of reference range if upper limit < 1.5 x N^#"},{"code":"2","display":"LDH2","definition":"1.5 – 10 x N^#"},{"code":"3","display":"LDH3","definition":"> 10 x N^#"}]}

package/CodeSystem-nkrs-liverdisease.json

@@ -0,0 +1 @@
+{"resourceType":"CodeSystem","id":"nkrs-liverdisease","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-liverdisease defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">0<a name=\"nkrs-liverdisease-0\"> </a></td><td>No (score 0)</td><td/></tr><tr><td style=\"white-space:nowrap\">1<a name=\"nkrs-liverdisease-1\"> </a></td><td>Mild (score 1)</td><td>Inclusive cirrhosis without portal hypertension. \r\nChild-Pugh-Score A; CLIF-SOFA Score 0. \r\n(ICD-10:, K70.0–K70.3, K70.9, K71.3–K71.5, K71.7, K73, K74, K76.0, K76.2–K76.4, K76.8, K76.9, Z94.4)</td></tr><tr><td style=\"white-space:nowrap\">2<a name=\"nkrs-liverdisease-2\"> </a></td><td>Moderate to severe (score 3)</td><td>Moderate liver disease: \r\ncirrhosis with portal hypertension, but without bleeding OR\r\nChild-Pugh-Score B OR\r\nCLIF-SOFA Score 1-2.\r\nSevere liver disease:\r\nChild-Pugh-Score C OR\r\nCLIF-SOFA Score 3-4, OR\r\ncoagulation disorder AND portal hypertension.\r\n(ICD-10: I85.0, I85.9, I86.4, I98.2, K70.4, K71.1, K72.1, K72.9, K76.5–K76.7)</td></tr></table></div>"},"url":"http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-liverdisease","version":"0.9.0","name":"NkrsLiverDisease","title":"NKRS - Liver Disease","status":"active","date":"2022-02-04T14:14:21+01:00","publisher":"Bundesamt für Gesundheit BAG","contact":[{"name":"Bundesamt für Gesundheit BAG","telecom":[{"system":"url","value":"https://www.bag.admin.ch/"}]}],"description":"The data item records the presence and severity of liver disease at the time of diagnosis \r\nas pre-existing medical condition. Scores weight the estimated effect on patient survival. \r\n\r\n**Liver Disease (Variable number: 10.2)** \r\nin \\'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part B1, SUPPLEMENTARY VARIABLES for Adults (15.10.2019)\\'\r\n([EN](https://www.nacr.ch/assets/files/uploads/b1-datadictionary-supplementaryvariables-adults-v1.1.pdf), \r\n[DE](https://www.nkrs.ch/assets/files/uploads/variablen-zusatzdaten-kinderjugendliche-v1.1.pdf), \r\n[FR](https://www.onec.ch/assets/files/uploads/b1-dict-des-donnees-variables-suppl-adultes-v1.1.pdf), \r\n[IT](https://www.snrt.ch/assets/files/uploads/b1-variabili-supplementari-adulti-v1.1.pdf))","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"CH"}]}],"copyright":"CC-BY-SA-4.0","caseSensitive":true,"valueSet":"http://fhir.ch/ig/ch-crl/ValueSet/nkrs-liverdisease","content":"complete","count":3,"concept":[{"code":"0","display":"No (score 0)"},{"code":"1","display":"Mild (score 1)","definition":"Inclusive cirrhosis without portal hypertension. \r\nChild-Pugh-Score A; CLIF-SOFA Score 0. \r\n(ICD-10:, K70.0–K70.3, K70.9, K71.3–K71.5, K71.7, K73, K74, K76.0, K76.2–K76.4, K76.8, K76.9, Z94.4)"},{"code":"2","display":"Moderate to severe (score 3)","definition":"Moderate liver disease: \r\ncirrhosis with portal hypertension, but without bleeding OR\r\nChild-Pugh-Score B OR\r\nCLIF-SOFA Score 1-2.\r\nSevere liver disease:\r\nChild-Pugh-Score C OR\r\nCLIF-SOFA Score 3-4, OR\r\ncoagulation disorder AND portal hypertension.\r\n(ICD-10: I85.0, I85.9, I86.4, I98.2, K70.4, K71.1, K72.1, K72.9, K76.5–K76.7)"}]}